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Abstract® 
 
A Multiple Case-Study Approach to Examine Police Officers Perceptions on Narcan® 
Policies. Casey Gnann, 2019: Dissertation, Nova Southeastern University, College of 
Arts, Humanities and Social Sciences, Department of Justice and Human Services. 
Descriptors: Law Enforcement, Opioid, Overdose, Naloxone, Narcan, Addiction, Harm 
Reduction 
 
In October 2017, President Trump officially declared the opioid epidemic to be a public 
health emergency. Reports from the CDC indicate that over 140 Americans die per day as 
a result of an opioid overdose (NPR, 2017). This statistic alone highlights the tragic 
effects of the current opioid climate. To date, an abundance of research has been 
conducted on opioid addicts, family members, doctors approach to addiction, etc. 
However, there is a gap in the research regarding law enforcement officers and their ever-
changing role in the fight against opioids. As the opioid epidemic has continued to 
worsen, many law enforcement departments have enacted policies, which require officers 
to carry and administer narcan [narcan is the nasal spray version of naloxone]. This 
dissertation sought to examine the perceptions of law enforcement officers who have 
been affected by the NS (nasal spray) naloxone policies.  
 
This study was designed to garner a better understanding of how law enforcement 
officers perceive this policy change. I utilized a qualitative approach in order to examine 
the first hand accounts from the participating officers. More specifically, a multiple case-
study design was employed, in order to examine the perceptions of each participant 
individually, as well as, collectively. The findings indicate police officers, often first to 
arrive on scene, recognize the importance of carrying nasal spray naloxone and the 
potential life saving ability. However, it was clear among the participant’s that Naloxone 
should not be viewed as a solution to the epidemic, rather a Band-Aid.  
 
Preliminary statistics for 2017, indicate opioid overdoses have continued to rise in the 
United States. As overdoses continue to rise, policy makers have continued to undergo 
fire for their failure to ignite change. Additionally, more and more police and Sheriffs 
departments have either enacted policy to equip officers with naloxone, or have received 
backlash for their failure to do so. It does not appear that the opioid epidemic will slow 
down anytime soon; therefore, it is more necessary than ever to determine how such 
policies may affect those involved. Police chiefs, law enforcement officials, and policy 
makers can utilize this study to further their understanding on law enforcements 
perceptions on carrying (NS) naloxone and harm reduction initiatives.   
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Chapter 1: Introduction 
Nature of the Research Problem 
In 2015, there were 52,404 lethal drug overdoses, 33,091 of which involved the 
use of an opioid (American Society of Addiction Medicine, 2016; Rudd et al., 2016). 
More specifically, 20,101 were attributed to prescription pain relievers, and 12,990 
related to heroin (American Society of Addiction Medicine, 2016; Rudd et al., 2016). In 
2016 the number of lethal drug overdoses in the United States reached 63,632 which 
represented a substantial increase from 2015. Additionally, in 2016 opioids were found to 
be involved in 42,249 of the overdose deaths, this represents a 27.9% increase from the 
data collected in 2015 (American Society of Addiction Medicine, 2016; Rudd et al., 
2016). The American Society of Addiction Medicine (2016) explained this escalation can 
predominantly be attributed to the increase synthetic opioid overdoses, which doubled 
from 2015 to 2016. A preliminary report released in August 2018, found there 72,306 
overdose deaths in 2017 (National Emerging Threats Initiative, 2018). This number 
represents an increase of 21% from the data provided in 2016.  Of the 72,306 fatal 
overdoses, 67.8% were found to involve opioids (National Emerging Threats Initiative, 
2018).   
To further demonstrate the significance of this epidemic, in February 2017 the 
State of Alaska declared a state of emergency, in response to the growing concerns of 
opioids. Not far behind, the States of Florida, Maryland, and Arizona also declared a state 
of emergency in 2017 (Rutkow and Vernick, 2017).  
From the late 1990s to present, we have continued to see a steady, often times 
substantial, increase in the use of opioids and subsequent number of opioid related 
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deaths. Given the constant rise of opioid use and the widespread havoc caused by this 
epidemic, it is more important than ever to address all aspects of the current opioid 
climate.  In the recent years there has been a push, straight from the White House, to 
equip law enforcement officers with an intranasal form of naloxone, also known as 
naloxone (The White House, 2013).  
Expecting officers to carry and administer naloxone represents a seismic shift in 
the typical duties of law enforcement officers. However, to date, little research has been 
conducted to examine the perceptions of these officers in regards to the shift in duties. 
This study aimed to bridge the gap in the research and develop a better understanding for 
how law enforcement officers feel about this added responsibility and the new role they 
are expected to play in the war on drugs. This topic is not only timely and relevant, but it 
also intended to give law enforcement officers an outlet to voice their opinions, on a very 
controversial, albeit significant topic.  
Background 
Hedegaard et al. (2017) found the age-adjusted rate of drug overdose deaths in the 
United States has tripled from 6.1 per 100,000 standard populations in 1999 to 19.8 in 
2016.  In August 2017, the Center for Disease Control and Prevention (CDC) released the 
provisional data for 2016, which reported 64,070 lethal drug overdoses in the United 
States from January 2016 to December 2016 (CDC, 2017). This represents a 22% 
increase from the 52,898 lethal drug overdoses reported in 2015 (CDC, 2017).  
The “Drugs Identified in Deceased Persons by Florida Medical Examiners 2016 
Interim Report”, which used data collected in the first half of 2016 (January through July) 
found the number of drug related deaths in Florida increased 13.9%, when compared to 
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the first half of 2015 (FDLE, 2016). Additionally, the same data set yielded deaths caused 
by fentanyl, heroin, and oxycodone increased 139.5%, 25.3%, and 17% respectively, 
when compared to the first half of 2015 (FDLE, 2016). As the opioid epidemic continues 
to plague the nation, we have seen a steady increase in opioid related deaths in the United 
States.  
In January 2016, the state of Florida reported 3,324 drug overdose related 
fatalities (CDC, 2017). The 2017 provisional data released by CDC indicated a 55% 
increase in January 2017. In the 13-month period between August 2015 and August 2016, 
provisional data collected by the CDC, indicated 4,091 reported drug overdoses in 
Florida (CDC, 2017). When compared to the following 12-month period, ending in 
August 2017, this number increased 35.9% to 5,559 fatal drug overdoses (CDC, 2017).  
There are countless statistics that can be inserted to demonstrate the gravity of the 
current opioid epidemic. However, grasping the overwhelming impact of this epidemic 
would be impossible without the first hand accounts of the first responders, the grieving 
family members who aspire to inspire change, and the addicts themselves who no longer 
recognize their reflection in the mirror. Since inception, the opioid epidemic has evolved 
from non-medical use of prescription medications to heroin to clandestinely produced 
synthetic opioids. The source of the drug may be a doctor, a neighbor, a friend, a Chinese 
laboratory found on the dark web, or a 14-year-old kid who stole his/her parent’s 
oxycodone.  This epidemic does not discriminate; people of all backgrounds, education 
levels, and socioeconomic status’ have and will continue to be affected.  
In November 2016, the Drug Enforcement Administration (DEA) denoted 
prescription opioids, heroin, and fentanyl as the principal drug related threats to the 
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United States.  Although prescription opioids, heroin, and fentanyl may fall under 
different schedules, they are similar in composition (DEA(F), 2016) ;(Rudd et al., 2016). 
Illicit drugs such as heroin and fentanyl may be viewed in a different light as prescription 
opioids, such as oxycodone, hydrocodone, methadone etc.; however, one thing that is 
consistent in opioid overdoses, is the need for naloxone. Naloxone is an opiate antidote, 
which works to block the opioid receptors and effectively reverses an overdose, for a 
limited period of time.  
Davis et al., (2014) reported, as of November 1, 2013, all 53 jurisdictions (50 
states, Washington, D.C., Guam and Puerto Rico) passed legislation which enabled 
paramedics to carry and administer naloxone. Notably, in many jurisdictions, paramedics 
have been carrying and administering naloxone for decades. However, as the sheer 
number of overdoses has continued to skyrocket, the need for expanded naloxone access 
has continued to be a timely and pertinent topic of debate. This discussion is particularly 
relevant in more rural areas, in which law enforcement officers may be able to respond 
significantly quicker than paramedic professionals.  
This study examined the thoughts and perceptions of police officers who have 
been mandated to carry and administer naloxone. As the opioid epidemic continues to 
plague the United States, police chiefs, especially those in rural areas, have received 
public backlash for their hesitation to equip their officers with naloxone. However, to 
date, there is minimal research which examines how the officers feel about this added 
responsibility.  
The relevance of this study is two-fold, for one, we are currently living through an 
opioid epidemic, in which naloxone has become the “life-saving drug”. Secondly, not all 
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law enforcement agencies have enacted legislation for officers to carry naloxone. 
Additionally, agencies which have enacted such policies may be experiencing difficulty 
in receiving and maintaining adequate funding measures to ensure the continuation of 
these policies.  
The current study allowed the writer to develop a first hand account of the 
insights and perceptions of various police officers, who are required by policy, to carry 
and administer naloxone. This study aimed to identify how law enforcement officers and 
their day to day interactions are affected by naloxone policies. Conducting this study 
using the perceptions and insights of the police officers affected, offered a different 
approach and fresh analysis of a pertinent and relevant topic. The results of this study 
provide policy makers and police chiefs a better understanding of police officers and how 
they may be affected by naloxone policies.  
Problem Statement 
The devastating effects of the opioid epidemic have resulted in numerous policy 
changes, designed to better address the growing number of opioid related overdoses. One 
of these policy changes directly affects the day to day responsibilities of many law 
enforcement agents.  According to the North Carolina Harm Reduction Coalition 
(NCHRC), as of November 2018, 2,482 law enforcement agencies in the United States, 
had enacted naloxone policies (NCHRC, 2017). Notably, this number only includes Law 
Enforcement agencies which have registered with NCHRC. This number will most likely 
continue to increase as opioid use and the prevalence of overdoses continues to increase.  
The administration of naloxone is often viewed as a medical procedure. In fact, 
paramedics have carried and administered naloxone since it’s inception. Therefore, it is 
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argued that naloxone policies for law enforcement represent a shift in their typical 
responsibilities. Notably, in the recent years’ naloxone has evolved and is currently 
available in a nasal spray, known as “Narcan”, which makes the application less 
cumbersome, than injecting application. With that said, there are potential complications 
that may arise when using a medication such as naloxone, designed to effectively reverse 
an opioid overdose.  
To the public eye as well as policy makers, these policies may seem necessary 
and possibly even overdue. However, this research serves to provide policy makers and 
law enforcement officials with the perceptions of law enforcement officers who are 
mandated to carry and administer naloxone.  
In 2016 a Florida Fire Rescue Department reported the agency administered 
naloxone to 289 people, of which, 193 showed improvements following administration. 
(Keever, 2017). In July of 2017, 125 doses of naloxone were administered by 
aforementioned Florida fire rescue department (Keever, 2017). About 64% of these cases 
reported improvements, following the use of naloxone (Keever, 2017). Equipping law 
enforcement officers with naloxone does not eliminate the need to call EMT/paramedics. 
However, law enforcement officers may often arrive on scene several minutes before 
EMT/paramedics. Depending on the nature of the overdose, several minutes could be the 
difference between life and death.  
In mid-2017, a Sheriffs Office located in Florida enacted policy which equipped 
officers with naloxone. In the two months following the inception of the naloxone policy, 
officers were on scene on nine occasions in which naloxone was administered (Keever, 
2017). Of the nine incidents, seven patients survived (Keever, 2017). On a small scale, 
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these seven lives shine a light on just how powerful naloxone can be in the war against 
opioids. It is important to note, the article consulted above, does not indicate whether the 
LEO’s or paramedics administered the naloxone.  
Theoretical Framework 
The conceptual framework for this study was derived from the theory of harm 
reduction. Costigan et al., (2003) defined harm reduction as “the prevention of adverse 
consequences of illicit drug use, without necessarily reducing their consumption” (p. 35). 
Fundamentally, harm reduction is a social policy which places the focus on reducing the 
harm associated with drug use, rather than focusing on reducing the illicit use of drugs 
(Newcombe, 1992). Proponents of harm reduction argue that achieving a drug free 
society is an unrealistic goal, which may hamper the implementation of measures 
designed to address the various harms associated with illicit drug use (Hunt, 2003). Harm 
reduction strategies represent a drastic shift from abstention policies, which typically 
employ a more punitive approach, designed specifically to decrease illicit drug use 
(Newcombe, 1992).    
In the war on drugs, harm reduction tactics may impact the day to day operations 
and expectations of police officers. This is particularly applicable in the discussion on 
equipping police officers with naloxone. This study aimed to develop a better 
understanding of police officer’s perceptions of the use of naloxone in the field, as it is 
important to differentiate between officer’s views on naloxone itself, and harm reduction 
collectively. 
Dissertation Goal  
The purpose of this research was to develop a better understanding of law 
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enforcement officer’s perceptions on the implementation of naloxone based policies. One 
may argue, the administration of naloxone would generally be considered a medical 
application. Therefore, requiring law enforcement officers to carry and administer 
naloxone would represent an unprecedented shift in law enforcement duties. However, as 
the opioid epidemic continues to plague the United States, it has become abundantly 
necessary to adjust current policies to better address the devastating effects of the 
epidemic. 
Currently, there is a gap in the research regarding law enforcement officer’s 
perceptions of these added duties. The goal of this research was to address this gap and 
develop a better understanding of how law enforcement officers, in the field, view this 
policy change, and how it may affect their day to day interactions and responsibilities. 
This research specifically focused on law enforcement officers who work for an agency, 
which has enacted and implemented naloxone policies.  
The findings from this study help fill the void in the research regarding law 
enforcement officers and their ever-changing role in the opioid epidemic. Ideally, this 
study will aid policy makers in the implementation of future policies regarding naloxone 
and law enforcement.   
Significance 
In many areas, law enforcement officers are able to respond to an emergency call 
significantly faster than the paramedics. For this reason, among many others, policy 
makers have sought to expand access of naloxone to law enforcement officers. To date, 
many high level discussions have taken place to discuss the pros and cons of equipping 
law enforcement officers with naloxone. Additionally, several studies have been 
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conducted to examine how these changes would affect the growing opioid epidemic. 
However, a review of the available literature indicated a gap in the research in regards to 
the examination of the attitudes and perceptions of the law enforcement officers, 
themselves.  Requiring law enforcement officers to carry and administer naloxone 
represents a seismic shift in their typical duties and responsibilities.  
In todays day and age, law enforcement officers are constantly under intense 
scrutiny. In fact, you can not turn on the news without watching some sort of exposé 
regarding an officer’s missteps or, at best, a critical analyzation of his/her every move. 
Yet, we are essentially demanding law enforcement officers to expand their already 
extensive laundry list of duties to now include an unambiguously, medical task.  
A podcast entitled “Policing Matters”, provides in depth discussions of applicable 
law enforcement topics, one episode previewed law enforcement officers who shared 
their thoughts on being equipped with naloxone. One officer stated  
I am not a paramedic; I did not sign up to be a paramedic. I am not a social 
worker; nor did not sign up to be a social worker. If someone does not want to 
possibly die when they take an illegal drug, don’t do it (Dudley & Willey, 2016, 
p.2).  
 
In fact, the majority of the comments, at least those presented in the podcast, appeared to 
be negative in nature. Another officer stated: “narcanned a guy three times in two days 
and he fought us every time, what a joke this world has become; tax dollars being spent 
to save drug addicts” (Dudley & Willey, 2016). In the case of equipping law enforcement 
officers with naloxone, it is clear that there may be a disconnect between the policy 
makers, and those individuals affected by the policies. 
Definitions of Terms 
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Analogue: According to the Drug Enforcement Administration “A controlled 
substance analogue is a substance which is intended for human consumption and is 
structurally or pharmacologically substantially similar to or is represented as being 
similar to a Schedule I or Schedule II substance and is not an approved medication in the 
United States” (DEA, n.d.).  
Bitcoin-  Bitcoin is a form of digital currency which allows the buyer to remain 
anonymous. Once a bitcoin is acquired, it is stored in a digital wallet, housed in the cloud 
or on the owner’s computer (Yellin, et al., n.d.).  Bitcoin transactions are logged; 
however, the identity of the buyer and sellers are not released. Instead, the users are 
tracked solely by their digital wallet number. For this reason, bitcoins have become the 
primary currency for illicit dark net marketplace transactions.   
Dark Web- Deep and dark web are often used interchangeably; however, this is 
not accurate. Thompson (2015) defined the dark web as “accessible, albeit anonymously 
hosted, websites that exist within the Deep Web” (p.1). In order to access the dark web, 
the user must utilize a software designed to mask the users IP address. The onion 
browser, aka TOR, is a commonly used software (Thompson, 2015).  
Darknet Marketplace: Anonymous marketplace which facilities the sale of 
potentially illicit materials. The use of the dark web protects the identity of the seller and 
consumer. Silk road is an example of a well-known illicit dark web marketplace.  
Deep Web- The deep web is the section of the world wide web, which is not 
indexed by customary search engines.  
Doctor shopping: Doctor shopping refers to patients who see multiple doctors in 
an attempt to receive several prescriptions within a short period of time. Specifically, an 
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individual is considered to be “doctor shopping” when he/she sees 5 or more prescribers 
and visits 5 or more pharmacies in a 90-day period. This allows patients to fill multiple 
prescriptions at one time, often for the same medication, unbeknownst to the providers.  
Prescription drug monitoring programs have helped physicians and pharmacists better 
monitor the actions of patients and therefore curtail the prevalence of doctor shopping.  
Drug Diversion: Drug diversion occurs when a legally prescribed controlled 
substance is transferred from the individual for whom the prescription is written to 
another individual, for an illicit purpose, such as use or sale. Drug diversion was 
extremely common during the “pill mill era”. Notably, the DEA employs countless 
“diversion investigators” a position designed to solely combat drug diversion.   
Naloxone- Naloxone is an FDA approved medication, used to prevent and reverse 
the effects of opioids. Naloxone is typically administered when an individual is 
undergoing an opioid overdose. The medication blocks opioid receptors and can reverse 
the damaging of the overdose (SAMHSA, 2016). 
Narcan- Naloxone is a form of naloxone that is administered through the nasal 
cavity. 
Oxy Express- The highway system in Florida gained the nickname “the oxy 
express”, due to the prevalence of overdoses which occurred while individuals were 
travelling to or from Florida in order to acquire OxyContin and other prescription drugs. 
Florida’s lax prescribing laws and the absence of a PDMP (until 2011) appealed to out of 
towners from states such as Kentucky with more stringent regulation.  
Pain Management Clinic: Health care clinics designed to detect, diagnose, and 
manage chronic pain.  
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PDMP: Prescription Drug Monitoring Programs. A PDMP is a state wide 
database which collects data pertaining to the dispensing of certain substances. PDMP’s 
are a resource used to combat prescription drug diversion and abuse.  
Pill Mil: A pill mill is typically used to describe a health clinic, doctor, or 
pharmacy that irresponsibly and recklessly prescribes and/or dispenses controlled 
substances (Rigg et al., 2010). 
Pill mill legislation- In 2011 Florida Attorney General Pam Bondi, worked in 
conjunction with the Florida Legislature to pass the “Anti-Pill Mill Bill.” This bill was 
created to enact various measures designed to address the Florida pill mill debacle.     
Schedules of Controlled Substances:  DEA (n.d.) explains “Drugs, substances, 
and certain chemicals used to make drugs are classified into five (5) distinct categories or 
schedules depending upon the drug’s acceptable medical use and the drug’s abuse or 
dependency potential” (p.1). Schedule 1 drugs have no approved medical use and are 
extremely addictive, whereas, schedule 5 drugs represent the lowest potential for abuse 
(DEA, n.d.).  
TOR: Software which allows access to the dark web 
Summary 
The direct goal of this research was to identify and further examine the 
perceptions of law enforcement officers regarding policies which equip officers with 
naloxone. In addition, this research was designed to fill the gap in research which fails to 
address the ever evolving role of law enforcement officers in the ever growing battle 
against opioids.  This dissertation provides policy makers, politicians, law enforcement 
management, and other consumers overdue data which may aid high-level discussions 
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regarding the role of law enforcement in the opioid epidemic. Ideally, this research 
allowed law enforcement officers the ability to provide truthful and meaningful data 
which will help guide future policy decisions.  
 In 1995 Purdue Pharma released the “extended release” version of OxyContin. 
Eight years later in 2007, the Federal Government criminally prosecuted Purdue Pharma 
for misleading consumers on the addiction potential of OxyContin, among other charges. 
In 2011, Florida began the crackdown on pill mills, through various legislative efforts 
including the pill mill legislation and the inception of PDMP’s. Finally, in 2018 President 
Trump signed an executive order calling for the establishment of a Presidential 
Commission designed to combat drug addiction and the opioid crisis.  
There is no argument that there are various efforts designed to combat the opioid 
epidemic; however, through the desperation associated with this growing epidemic, law 
enforcement officers have seen a shift in their responsibilities. Officers who were once 
instructed to crack down on drug use are now expected to carry and administer an opioid 
reversal applicator. Additionally, Good Samaritan legislation principally prevents officers 
from charging drug users using information or illicit paraphernalia identified when 
responding to an overdose. My goal in conducting this research was to address law 
enforcement officer’s outlook on these policies and in turn their evolving role in the 
opioid epidemic. The results of this study can be used to aid law enforcement officials 
and key decision makers in future policy decisions regarding law enforcement’s role in 
combating the opioid epidemic.   
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Chapter 2: Literature Review 
Coverage  
This literature review sought to develop a better picture of the opioid epidemic. In 
order to conduct a comprehensive review of the literature, numerous databases were 
utilized. Primary databases include: Academic One File, JSTOR, National Criminal 
Justice Reference Service, ProQuest, General One File, LexisNexis, Sage Online, 
ScienceDirect, Taylor and Francis Online. The initial searches included terms such as: 
“prescription pill” “opioid”, “addiction”, “heroin”, “fentanyl”, “naloxone”, and “narcan”. 
These terms were cross referenced with the terms such as: “mortality,” “addiction,” 
“epidemic,”, “law enforcement”, and “overdose”. The studies that fit the criteria for the 
literature review were sorted based on the topic of the study. Once the categories were 
determined, the articles in each category were organized by the date of publication. 
Sorting by date allowed the writer to focus on the more recent articles, when available. 
This literature review includes a variety of different types of studies, including 
quantitative, qualitative, and mixed methods.  Additionally, due to the topic at hand, 
many of the research included was published by government entities. The literature 
review is broken up in to three sections. The first section will discuss the opioid epidemic 
as a whole, the second section examines the transition from licit to illicit opioids, and the 
third section presents the topic of naloxone.  
Theoretical Framework 
In the recent decades we have begun to see a shift from abstention related policies 
to harm reduction strategies, in an attempt to minimize the ever growing harms associated 
with the opioid epidemic. Marlatt (1998) defined harm reduction as “an umbrella term for 
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interventions aiming to reduce the problematic effects of behaviors (p.1).” Although a 
harm reduction stance can be employed for a myriad of different topics, this review will 
focus primarily on the use of harm reduction in drug policy. 
 Harm reduction policies such as needle exchange programs, naloxone 
distribution, safe injection sites, etc. are designed to reduce the harms associated with 
drug use. However, adversaries argue these policies hinder abstention goals and may 
even enable drug users (Logan & Marlatt, 2010). Harm reduction tactics are controversial 
and often criticized. Notably, law enforcement officers are typically not consulted in the 
development and implementation of harm reduction policies. Yet, they may be expected 
to obey policy directives that fall in direct contention with their typical guidelines.   
 Many harm reduction strategies and policies require the participation and 
execution of law enforcement officials. In the recent decades, Vietnam has experienced 
difficulty in the implementation of harm reduction policies and the necessary 
participation of law enforcement officers. However, a study conducted in 2012, indicated 
issues arose due to a lack of communication and leadership. Jardine et al., (2012) found 
the majority of the law enforcement individuals interviewed felt conflicted with the 
newfound responsibilities associated with harm reduction policies. Additionally, 
interviewees noted a lack of training and education for policeman in regards to harm 
reduction theories and policies (Jardine et al., 2012). An overwhelming majority of the 
participants explained the change in policies did not warrant a change in performance 
measures. Therefore, police officers were expected to meet numbers and predetermined 
statistics that did not necessarily align with harm reduction practices (Jardin et al., 2012).  
   One of the harm reduction strategies that has been employed in the recent 
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decades, is the widespread availability of naloxone. Policy makers coupled with 
pharmacies have worked together to develop looser guidelines, designed to make 
naloxone more readily available for addicts, friends of addicts, family members, etc.  
Additionally, police chiefs around the United States have implemented policies designed 
to equip law enforcement officers in the field with NS (nasal spray) naloxone. However, 
adversaries of harm reduction strategies argue that providing easy access to naloxone 
may encourage users to overindulge or use recklessly. Law enforcement officers are 
expected to obey policy measures, regardless of personal opinion. This research 
examined law enforcement officer’s perceptions of the use of naloxone in the field as 
well as their perceptions of harm reduction techniques.  
Prescription Opioid Epidemic 
The abuse of prescription and illicit opioids has skyrocketed in the recent decades, 
resulting in a crisis affecting virtually all aspects of society. From the 1990s to the present 
we have seen a notable increase in the prescribing of opioids, use of opioids, and rate of 
drug overdoses. In the time period between 1997 and 2007, opioid prescriptions in the 
United States skyrocketed 700% (Boyer, 2012). From 1999 to 2014 drug overdose deaths 
in the United States, practically tripled (Rudd et al., 2016).  In 2010, the annual number 
of opioid prescriptions reached 210 million, an increase of 135 million from 1991 
(Guohua et al., 2014; National Institute on Drug Abuse NIDA 2011; Volkow 2008; 
Volkow and McLellan 2011). The National Survey on Drug Use and Health (NSDUH) 
anticipated 12.5 million Americans misused a prescription medication in 2015 
(SAMHSA, 2016). In 2014, 47,055 deaths were found to be a direct result of a drug 
overdose, 28,647 of which were determined to have involved an opioid (Rudd et al., 
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2016). In 2015, 52,404 deaths were found to be a direct result of a drug overdose, 33,091 
of which were found to have involved an opioid (Rudd et al., 2016). In the one-year 
period between 2014 and 2015, drug overdose deaths increased 11.4% (Rudd et al., 
2016). In the same time period, opioid death rates increased by 15.6% (Rudd et al., 
2016).  
In 2015, the DEA reported "overdose deaths, particularly from prescription drugs 
and heroin, have reached epidemic levels" (DEA, 2014, p.2). Rudd et al. (2016) reported 
the drug overdose death rate substantially rose from 12.3 per 100,000 populations to 16.3 
per 100,000 populations, in 2010 and 2015, respectively. The United States experienced a 
monumental increase in the number of dispensed opioids as well as the number of drug 
overdoes from the 1990s to the current day. Perhaps most notably, is the substantial 
increase in opioid related overdoses, and subsequent fatalities. Prior to 2011, the Drug 
Abuse Warning Network (DAWN) kept track of the number of hospital visits which 
involved pharmaceutical opioids. From 2004 to 2011, DAWN found medical 
emergencies involving pharmaceutical opioids rose 183% (SAMHSA, 2011). This 
number likely would have continued to increase; however, DAWN was discontinued by 
SAMHSA.  
The five-year period between 2010 and 2015 saw a 2.6% increase in the death 
rates for natural semisynthetic opioids, 20.6% increase in the death rates for heroin, and 
72.2% increase in the death rate for synthetic opioids, excluding methadone (Rudd et al., 
2016). These increases were consistent among all demographics and locations. The years 
between 2010 and 2015 saw a 9.1% decrease in the methadone death rates (Rudd et al., 
2016). Rudd (2016) attributes the reduction, to increased efforts in the early 2000s to 
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reduce the use of methadone. In late 2016, the DEA classified prescription drugs, heroin, 
and fentanyl as the top drug-related threats to the United States (Rudd et al., 2014).  
Provisional data collected by the CDC indicated, in the 12-month period between 
August 2015 and August 2016, there were 59,417 drug related overdose deaths (Ahmad 
et al., 2018). When compared to the following 12-month period ending in August 2017, 
this number increased 13.3% to 67,344 overdoses (Ahmad et al., 2018). Of the 67,344 
drug overdoses reported from August 2016 to August 2017, 45,200 were found to be 
caused by opioids (Ahmad et al., 2018). Of the opioid related overdoses (45,200) 
synthetic opioids, heroin, and natural/semi synthetic opioids attribute for roughly 25,382, 
15,358 and 14,344, respectively (Ahmad et al., 2018). Notably, the number of synthetic 
opioid related overdoses increased from 15,256 in the period ending in August 2016 to 
25,382 in August 2017 (Ahmad et al., 2018). 
NSDUH projected “30.5 million Americans aged 12 or older were current illicit 
drug users” (SAMHSA, 2018).  NSDUH defined a current drug user as an individual who 
had used an illicit drug in the last month (SAMHSA, 2018). When categorized by drug of 
choice, marijuana was found to be the most commonly used (26.0 million), followed by 
prescription pain relievers (3.2 million). In 2017, NSDUH estimated 2.1 million people 
were suffering from opioid addiction (SAMHSA, 2018).  The overwhelming majority 
(1.7 million) were said to have a prescription pain reliever use disorder, whereas the 
remaining (.7 million) were found to misuse heroin (SAMHSA, 2018).    
When discussing drug overdose statistics, it is important to note the difficulty in 
ensuring the accuracy of the data. Drug overdoses often occur when an individual ingests 
more than one type of drug. However, depending on the timeliness of the autopsy it may 
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be difficult, if not impossible, for the medial examiner to determine which drug in fact 
caused the overdose. Hedegaard et al. (2017) noted that in about 1 in 5 drug overdoses, 
the type of drug is not listed on the medical certificate. With that said, it is possible that 
the number of opioid involved overdoses is underreported.  
As news stations continue to inundate viewers with heart wrenching statistics, 
politicians aim to present their angle on the daily circuit, and the White House works to 
develop a plan to tackle the ever-growing epidemic, we still appear no closer to a drug-
free society. Each state has taken it upon themselves to develop legislation designed to 
better combat the opioid epidemic in their respective territories. However, addicts 
continue to outsmart the system and exploit areas with weaker legislative policies. This 
literature review aimed to deeply explore the opioid epidemic, more specifically, the 
series of events which cultivated an environment conducive to growing the epidemic, the 
growth and danger of synthetic opioids, and the importance of naloxone in working to 
prevent opioid related overdoses from turning fatal. 
Defining “Pain”.  In 1998, pain, was officially classified as the fifth vital sign (Quinones 
2015). Essentially, pain is now viewed in the same category as pulse, blood pressure, 
respiration, and body temperature. (Quinones 2015). This classification represented a 
seismic shift in the way the medical community responded and treated a patient’s pain 
level. Prior to the second half of the 1900s, many doctors publicly expressed their distaste 
for pain management treatment. These medical professionals argued pain was beneficial 
to the patient and a necessary component of the healing process (Lembke 2012). 
However, as medicine began to evolve, views on pain followed in suit.  
In the late 1980s, medical professionals were encouraged to view pain as a 
   
 
 
 
 
  
 
 
 
21 
 
 
 
 
 
 
subjective experience for the patient (Lembke 2012). This notion was reinforced through 
the use of patient satisfaction surveys. A typical patient satisfaction survey includes a 
component pertaining to the doctor’s ability to address the patients pain (Lembke 2012). 
The results of these surveys may be used to determine a physician’s bonus, job security, 
etc. Doctors who refuse to prescribe pain killers to patients who describe their pain level 
using terms such as "unbearable", “intolerable”, “debilitating”, etc., may be viewed as 
withholding necessary treatment measures. One patient summed up the conundrum 
doctors face, she stated: I'm addicted to (opioids) and its the doctors fault because they 
prescribed them. But I'll sue them if they leave me in pain" (Lembke, 2012 p. 2).  
A typical medical professional does not undergo extensive training in pain 
management. However, on job training indicates that a quick visit with a patient resulting 
in a pain prescription is more cost effective than the alternative. Doctors who choose to 
take the time to educate their patients on addiction or utilize counseling techniques may 
be criticized for their inability to "turn patients over" quickly and efficiently. These 
shifting views coupled with the popular notion that pain counteracts the euphoric effects 
of opioids, led to disaster. As physicians began to open their mind to the use of 
prescription opioids, pharmaceutical companies such as Purdue Pharma, seized the 
opportunity. 
Big Pharma. OxyContin was first introduced by Purdue Pharma in 1996 (Zee, 2009). 
Purdue Pharma revolutionized the advertising tactics for pain medicine. They utilized 
aggressive techniques and substantial monetary incentives to capture the market. In 2000, 
OxyContin sales reached over $1 billion, a substantial increase from the $48 million 
posted in 1996 (Zee, 2009). These financial strides were the result of aggressive 
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advertising coupled with a liberalized approach to pain management (Zee, 2009).  In the 
five-year period between 1996 and 2001, Purdue Pharma held over 40 national 
conferences, in which more than 5,000 medical professionals accepted invitations to 
attend, free of charge (Zee, 2009). While in attendance medical professionals were 
recruited and subsequently trained to speak on behalf of Purdue Pharma. Zee (2009) 
explained, Purdue Pharma specifically targeted doctors who demonstrated high 
prescribing tendencies. Additionally, Purdue Pharma developed a lucrative incentive 
system, designed to motivate sales representatives to utilize any and all marketing tactics 
to increase sales in their respective territories (Zee, 2009). In 1996, the Purdue Pharma 
sales force consisted of 318 employees, this number increased to 671 by 2000 (Zee, 
2009). Sales representatives inundated doctors with OxyContin merchandise such as hats, 
pens, t-shirts, etc. Perhaps most notably, a chart which indicated a patient’s prescription 
for another pain pill being crossed out and replaced with OxyContin (Quinones 2015). 
Additionally, Purdue Pharma distributed a coupon which allowed new patients to receive 
a free supply of OxyContin (Zee, 2009). On the topic of the OxyContin marketing 
campaign, the DEA stated no company had ever utilized such tactics in the advertising of 
a schedule II drug (Quinones, 2015).  
Purdue Pharma utilized numerous different avenues such as videos, conferences, 
spokesman, etc to inform consumers that the chance of patients becoming addicted to 
OxyContin was extremely rare.  Purdue Pharma cited the timed release formulation of 
OxyContin to present the idea that it was less addictive. The company relayed that the 
slow release of the opioid, prevented patients from experiencing extreme highs and lows, 
which are prevalent in addiction (Zee, 2009).  In fact, sales representatives were trained 
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and encouraged to communicate the message that the chance of addiction was "less than 
one percent" (Zee, 2009, p. 223). Purdue Pharma exploited the limited staff of the Food 
and Drug Administration (FDA) and released OxyContin promotion video to medical 
professionals prior to receiving the stamp of approval from the FDA. This video was later 
deemed inappropriate due to the minimization of the risks and promotion of the 
unsupported benefits. However, in 2007 a partner company of Purdue Pharma, Purdue 
Frederick Company Inc., along with 3 high ranking employees pled guilty to the 
misrepresentation of OxyContin (Zee 2009). They were subsequently ordered to pay 
$634 million. 
In August 2010, Purdue Pharma released a new version of OxyContin. This 
version was designed to help prevent users from crushing and subsequently snorting or 
injecting the pills. Data collected from the Rocky Mountain Poison Control Center Drug 
Diversion Monitoring Program demonstrated a substantial decrease in the demand for 
OxyContin, following the release of the new formula (Severston et al., 2016). The same 
data set, yielded the illicit market price for OxyContin, dropped 50 percent, following the 
release of the reformulated pill (Severston et al., 2016). Cicero et al., (2012) conducted a 
study to gauge the effectiveness of the reformulation. Prior to the release, 35.6% of 
survey respondents designated OxyContin as their preferred drug of choice (Cicero et al., 
2012). This percentage dropped to 12.8%, 21 months following the release of the 
reformulated pill. All of the participants who admitted to abusing both versions of 
OxyContin, preferred the original formula (Cicero et al., 2012). 66% of participants, who 
previously indicated OxyContin as their drug of choice, switched to a different opioid 
(typically heroin) following the release of the reformulation (Cicero et al., 2012). One 
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participant stated “most people that I know don’t use OxyContin to get high anymore. 
They have moved on to heroin [because] it is easier to use, much cheaper and easily 
available” (Cicero et al., 2012). It is important to note, the statement above, although not 
necessarily corroborated with statistical data, may be a strong indication for the gateway 
between prescription opioids, specifically OxyContin, and heroin use.   
Prescription Drug Monitoring Program. The National Alliance for Model State Drug 
Laws defines a prescription drug monitoring program (PDMP) as a centralized, 
comprehensive database which houses statewide data regarding prescribed substances 
(DEA, 2016). Currently, most states require practitioners to diligently update the PDMP 
with patient information, including but not limited to, prescription history, prescriber 
information, specific dosage details, current medications, etc. (Astho, n.d.). Depending on 
the state, this information may be provided to various agencies or parties such as public 
health agencies, physicians, public safety agencies, pharmacies, etc. (Astho, n.d.).  
The first PDMP was established in California in 1939 (Blumenschein et al., 
2010). By the early 90s, 10 states had active PDMPs (Blumenschein et al., 2010). At this 
time, there was no blueprint for the establishment of a PDMP. As a result, each PDMP 
differed in the design of the program. The overall goal of the early PDMPs was unified 
among the states. Unfortunately, the lack of standardization among these programs made 
it increasingly difficult to open the lines of communication and share information among 
neighboring states.  
In the early 2000s, the abuse and diversion of controlled substances continued to 
increase. With the financial support of Congress, the Bureau of Justice Assistance (BJA), 
Office of Justice Programs in the U.S. Department of Justice, established the Harold 
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Rogers Prescription Drug Monitoring Program (Blumenschein et al., 2010). These grants 
were designed to assist states in the planning, implementation, or enhancement of a 
PDMP. The U.S. Department of Health and Human Services, followed in suit and created 
the National All Schedules Prescription Electronic Reporting Act (NASPER) 
(Blumenschein et al., 2010). NASPER funds were designed to be used in the creation or 
improvement of a state PDMP (Blumenschein et al., 2010). For the Harold Rogers Grant 
and NASPER, President Obama proposed allocating seven million and two million, 
respectively, in the budget for fiscal year 2010 (Blumenschein et al., 2010.  
Each state has the autonomy to develop and utilize the PDMP to best serve the 
needs of the state. The majority of established PDMPs are housed in the state public 
health agency; however, a handful of states house the PDMP with a law enforcement 
agency (Astho, n.d.). The administrative details as well as the housing agency differs 
among states; however, the underlying concept of the PDMP is typically similar 
(Blumenschein et al., 2010). Generally, PDMPs are established in an attempt to combat 
the diversion of controlled substances. However, many states cite the importance of 
improving the pharmaceutical treatment of patients (Astho, n.d.). Critics of PDMPs cite 
the danger of refusing to prescribe patients who are in legitimate pain.  
The lack of uniformity among state PDMP's has made it increasingly difficult for 
states to share PDMP data. As a result, doctor shoppers may travel across state lines to 
receive prescriptions from doctors, unaware of their medical history in other states. Other 
differences in PDMPs among states may include the number of scheduled drugs included 
(Gugelmann et al., 2012). For example, the PDMP in Pennsylvania only requires medical 
professionals to track the dispensing of Schedule II drugs (oxycodone, and 
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hydromorphone et al). More commonly, PDMPs require the tracking of Schedules II-IV 
(Gugelmann et al., 2012). Additionally, states may differ in the period of time allowed 
before updating the system (Gugelmann et al., 2012). For example, Florida allows 
medical professionals and pharmacies a seven-day window to update the system with 
newly acquired data.  
Another difference among states is the accessibility of the PDMP. Typically, 
states allow a combination of pharmacists, prescribers, medical professionals, and law 
enforcement agencies, limited or full access to the database. Various law enforcements 
agents have expressed frustration with their lack of access to the information housed in 
the PDMP. Gugelmann et al. (2012) stated there are a handful of states which prevent 
prescribers from accessing the data available on the PDMP before prescribing a 
controlled substance. This legislation is designed to prevent the prescriber from facing 
civil liability. One could argue this policy may negate the purpose of the PDMP. The 
inability of out of state data sharing among many states limits the effectiveness of 
PDMPs. In fact, the differences among states, allows addicts to exploit the weaknesses of 
various states and reap the potential benefits of less stringent legislation. 
Climate in Florida. In the early 2000s, Florida was viewed as the hub for prescription 
drug diversion. Addicts from neighboring states travelled down I-95S, often referred to as 
“the oxy express”, to Florida to obtain prescription medication. As more states began to 
implement PDMP legislation, Florida became a haven for traffickers and those addicted 
to opioids. The lax regulatory oversight of physicians and pharmacies coupled with the 
lack of a prescription drug monitoring program cultivated an environment conducive to 
prescription drug diversion (Florida Board of Medicine, 2014).  In the five-year time 
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period between 2005 and 2010, the prevalence of oxycodone related deaths in Florida, 
jumped 345% (Department of Justice, AG Remarks, 2011).  
Johnson et al. (2014) stated in 2010, 98 of the top 100 oxycodone dispensing 
prescribers were located in Florida. In 2010 the DEA reported the state of Florida was 
home to at least 900 unregulated pain management clinics (Florida Board of Medicine, 
2014). All but one of the top 50 oxycodone dispensing pain clinics, were located in 
Florida (Florida Board of Medicine, 2014).  These clinics alone were responsible for the 
sale of more than one million oxycodone pills each month (Florida Board of Medicine, 
2014). Using data provided from the Florida Medical Examiners yearly reports, it was 
estimated that each day about ten people die from drug overdose. (Florida Board of 
Medicine, 2014). Per 100,000 populations, oxycodone related deaths in Florida 
skyrocketed 265% and 118.3%, between 2003 and 2009 and 2007 and 2010, respectively. 
Johnson et al. (2014) reported between 2003 and 2010, the frequency of deaths resulting 
from drug overdose jumped 58.9%.  
The “Drugs Identified in Deceased Persons by Florida Medical Examiners 2016 
Interim Report”, which used data collected in the first half of 2016 (January through 
June) found the number of drug related deaths in Florida increased 13.9 percent, when 
compared to the first half of 2015 (FDLE, 2016). Additionally, the same data set yielded 
deaths caused by fentanyl, heroin, and oxycodone increased 139.5%, 25.3%, and 17% 
respectively, when compared to the first half of 2015 (FDLE, 2016). As the opioid 
epidemic continues to plague the nation, we have seen a steady increase in opioid related 
deaths in the United States.  
A qualitative analysis conducted on law enforcement perceptions of prescription 
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pill abuse indicated that many law enforcement officers were quick to disregard the 
severity of the prescription pill addiction (Gau and Brooke, 2017). With "hard" drugs 
such as heroin, cocaine, meth, etc on the streets, there was little time to focus on a doctor 
prescribed medication. One law enforcement officer stated "five, 6 years ago, it was like 
the Wild, Wild West. There was no regulation. They [pill-mill physicians and owners] 
weren't afraid. They in no way had any fear of arrest of being incarcerated or anything 
like that" (Gau and Brooke, 2017, p. 196). Gau and Brooke (2017) found the law 
enforcement officers interviewed, overwhelmingly supported the notion that, in the last 
few years, the prevalence of prescription pill mills decreased substantially in Florida 
(Gau and Brooke, 2017). Notably, a portion of the individuals interviewed argued that the 
pain clinics may have outsmarted the system and simply relocated (Gau and Brooke, 
2017).   
In the recent years, we have seen an increase in the successful prosecution of 
doctors involved in pain management clinics. However, in order to charge a physician 
under the Florida Statues regarding lawful prescription of controlled substances, the 
prosecutor must prove the physician "knowingly" prescribed opioids to patients who 
were abusing the medication or distributing for financial gain (Gau and Brooke, 2007). 
Essentially, the prosecutor must prove the doctor incorrectly gauged the level of pain, 
experienced by the patient. Pain management clinics are essentially legal, as is the 
distribution of prescription opioids. Therefore, law enforcement and prosecution must 
identify and prove the criminal intent of a generally, legal operation. Law enforcement 
officers cited numerous difficulties in building air tight cases against physicians. For one, 
doctor-patient confidentiality makes it difficult for law enforcement officers to gain 
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access to a patient’s medical records. Additionally, and perhaps most notably is the 
knowledge possessed by physicians. One law enforcement officer mentioned he was ill-
equipped to determine how many pills and patient should receive, which made it difficult 
to prove ill intent.  
Diversion of Prescription Pills. The overwhelming presence of pain clinics or "pill 
mills" coupled with the ease of obtaining prescriptions for opioids and onsite pharmacies 
created the perfect combination for diversion. In this case, diversion is the act of 
transferring legally obtained prescription opioids out of the control of the individual for 
whom it was prescribed and distributing for illicit use (Surratt et al., 2014). The lack of 
pill mill legislation in Florida, throughout the first decade of the 2000s, made it extremely 
difficult to identify and subsequently combat instances of diversion. Many patients 
utilized the concept of "doctor shopping" to acquire additional prescriptions. A “doctor 
shopper” is a patient who actively seeks medical prescriptions from multiple doctors 
without informing the other doctors of their acquired prescriptions. In a study conducted 
in the United States, researchers concluded the average doctor shopper received 32 
prescriptions for opioids from ten different medical professionals (Melville 2013). Other 
methods which often lead to diversion include forging prescriptions, stealing from 
patients or pharmacies, and under the counter sales by physicians. Between 2008 and 
2010 pill mills were found to be the primary source of prescription opioids sold on the 
illicit market (Surratt et al., 2014).  
In 2014, the NSDUH, reported the majority (63.6%) of illicit prescription pill 
users, received the drugs from friends or relatives (Substance Abuse and Mental Health 
Services Administration, 2014). The remaining individuals received the drugs from 
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physicians (21%), drug dealers (4.3%) and online avenues (0.1%) (Substance Abuse and 
Mental Health Services Administration, 2014). 
Using law enforcement data in Florida, researchers found the diversion rates of 
oxycodone and several other opioids, decreased following the PDMP implementation and 
various legislative efforts (Surratt et al., 2014). Surratt (2014) found that the diversion of 
fentanyl, hydromorphone, buprenorphine, and tramadol neither increased nor decreased 
during the period of analysis.  
Florida Response. In the early 2000s, the Federal Center for Disease Control denoted 
Florida as the epicenter of prescription drug diversion. Until 2009, Florida failed to enact 
any legislative policies designed to combat the proliferation of pill mills and the 
overwhelming diversion to illicit markets. In 2009, the Florida legislature approved the 
passing of a law designed to address the states rising issue with prescription drug abuse 
and diversion (Florida Board of Medicine, 2014). Prior to the implementation of the 
PDMP, Florida introduced the pain clinic legislation (PCL) in October 2010 (Surratt et 
al., 2014). The PCL initiative sought to address pain clinic ownership, streamline the 
inspection and registration of pain clinics, limit cash transactions, and eliminate the 
ability to dispense substances in the same place as the patient doctor interaction (Surratt 
et al., 2014).  
In 2009, the Miami division of the DEA, created the Tactical Diversion Squad 
(TDS), in Weston Florida. The TDS was designed to bridge a partnership between the 
DEA’s subject matter experts and the various law enforcement partners. This force 
specifically focuses on the Controlled Substance Act and statues associated with 
diversion of pharmaceuticals (DEA, 2013).  The early success of the TDS in Weston 
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encouraged the DEA to expand these forces to Tampa, Orlando, and West Palm Beach 
(DEA, 2013).  In 2010, Florida enacted policy which required pain management clinics to 
register with the Department of Health by January 4, 2010 (Delcher, et al., 2015) 
(Johnson et al., 2014).  
In February 2010, the DEA partnered with various Florida law enforcement 
agencies to form a joint task force to combat prescription pill diversion. This partnership 
was responsible for numerous victories, perhaps most notably was Operation Oxy Alley. 
The outcome of this operation was 32 arrests, on various key players in the pill mill 
industry, including doctors and pill mill owners (Kennedy-Hendricks et al., 2016). 
 In February 2011, the DEA again colluded with over 500 state and local law 
enforcement officers to target pill mills. The immediate results included the execution of 
21 search warrants in various South Florida locations, 25 arrests on the basis of drug and 
money laundering charges, the seizure of almost $10 million in assets, and numerous pill 
mill shutdowns (DEA Diversion PPT, 2013). This massive operation dubbed “Operation 
Pill Nation” led to the subsequent enactment of Operation Pill Nation: II. Together, these 
operations have led to the closure of more than 40 pain clinics, 100 arrests, at least 80 
DEA registrations were capitulated, and almost $20 million in assets seized (Department 
of Justice, AG Remarks, 2011).  
Florida Statute, 893.055 authorized the creation and implementation of a 
comprehensive, electronic database, designed to house information regarding the 
prescription of controlled substances (FL Statue 893.055). Florida Statue 893.055 
provided stringent guidelines to existing pain clinics, in an attempt to curtail the 
overwhelming amount of prescription drug diversion, in the early-mid 2000s (Florida 
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Board of Medicine, 2014).  
In 2011, the Electronic-Florida Online Reporting of Controlled Substances 
Evaluation (E-FORCSE) became operational. E-FORSCE is housed by the Department 
of Health and funded though a non-profit, direct support organization (Florida Board of 
Medicine, 2014). The Florida PDMP requires pharmacies and physicians to update the 
record in the system within seven days of dispensing a controlled substance (Surratt et al., 
2014). 
Soon after the implementation and launch of E-FORSCE, Florida overhauled the 
existing registration requirements for medical clinics, in the prescription pill industry 
(Gau and Brooke, 2017).  At this time, Florida coined the term "pain- management 
clinic", as any facility which advertised pain-management services, or if 50% of the 
patient population in one month was prescribed opioids, benzodiazepines, barbiturates, or 
carisoprodol (Gau and Brooke, 2017). This legislation provided local law enforcement 
agencies as well as the DEA, the ability to better track and monitor these pain-
management clinics.  
In July 2011, Florida Governor Rick Scott, signed FL House Bill 7095 into law. 
FL House Bill 7095 commonly referred to as the "pill-mill law" enacted increasingly 
stringent guidelines regarding pain management clinics. First, this legislation prevented 
medical practitioners from dispensing prescription opioids on site (FL House Bill 7095, 
2011). It was a common practice of pill-mills to profit greatly by dispending the 
prescriptions out of the same locations in which they were prescribed. This not only 
eliminated the hassle of travelling to a second location, but also allowed patients 
immediate access to the opioid, and eliminated any fear of getting rejected at a pharmacy. 
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Additional regulations included new inspection standards for pharmacies, and a reduction 
in the amount of time allowed for PDMP reporting (FL House bill 7095, 2011). Lastly, 
the House Bill 7095 legislation redefined patient treatment standards, and enacted more 
stringent penalties on physicians who failed to comply.   
The Florida Board of Medicine (2014) reported a 41% decrease in the oxycodone 
death rates, since the implementation of E-FORSCE. From the date of inception till July 
2014 over 112 million records regarding the dispersion of controlled substances have 
been entered in to E-FORCE (Florida Board of Medicine, 2014). In 2014 the Florida 
Board of Medicine (2014) reported over 25,000 practitioners had registered for E-
FORSCE, which included 8,259 Medical Doctors who were found to actively utilize the 
system. In the time period between 2010 and 2012, oxycodone prescriptions decreased 
52% in Florida (Johnson et al., 2014).  
Delcher et al. (2015) identified an inverse relationship between PDMP searches 
and oxycodone-caused deaths. Delcher et al. (2015) found a 25% decline in oxycodone-
caused mortality following the implementation of E-FORSCE in October 2011. 
Additionally, oxycodone-alprazolam, alprazolam, and benzodiazepines-caused deaths 
also declined following the implementation E-FORCSE (Delcher et al., 2015). It is 
important to mention the Abuse-Deterrent Formulation of OxyContin® was released in 
2010. Studies have demonstrated a decrease in the use of OxyContin following the 
reformulation. This relationship is further explored on page 42.   
Current Climate. Numerous studies have concluded that the efforts and legislation in 
Florida, designed to combat the illicit use and diversion of controlled substances, was 
overwhelmingly successful. Following the various legislative efforts between 2010 and 
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2013, Florida reported about 250 pain clinics closed (Johnson et al., 2014).  Additionally, 
the number of top quantity oxycodone prescribers went from 98 to 13 to 0 in 2010, 2012, 
and 2013, respectively (Johnson et al., 2014). Johnson (2014) stated, Florida law 
enforcement agencies reported the diversion of controlled substances decreased between 
2010 and 2012 (Johnson et al., 2014).  
Due to the close proximity of various measures, it is near impossible to determine 
the individual effect of each of the legislative efforts in Florida designed to curb 
prescription pill distribution and subsequent diversion. Gau and Brooke (2017) conducted 
a study in which they sought to examine the comprehensive impact of these legislative 
efforts. Gau and Brooke (2017) found a 50% decline in the number of pain management 
clinics in Florida, from 2009 to 2014. Additionally, the number of pain management 
clinic applications rapidly declined following the legislative efforts in 2010 and 2011 
(Gau and Brooke, 2017). This provides support for the notion that the various legislative 
action enacted in Florida in 2010-2011 was successful in limiting new pain management 
clinics.  
As mentioned above, in the time period between 2009 and 2011, Florida 
unleashed a series of legislative efforts designed to reduce the number of pill mills in 
operation. Although met with wide success, many medical professionals have attributed 
the increase in heroin use and related overdoses, to the crackdown on the prescription 
opioid market. Many prescription opioid non-medical users utilized “legal” methods to 
obtain hundreds of prescription opioid pills. As a result, a large percentage of these users 
became dependent on the prescription opioids. However, with the “crackdown” in 
Florida, these users were left addicted to opioids with no legal avenue to obtain the 
   
 
 
 
 
  
 
 
 
35 
 
 
 
 
 
 
opioids necessary to maintain the addiction. James Hall, an epidemiologist in South 
Florida, explained Florida has yet to establish adequate treatment avenues for the 
prescription opioid users who are addicted to a medication they are unable to legally 
access (American Medical News, 2013).  
Kennedy-Hendricks et al. (2016) conducted a study in which they used 
conservative assumptions to examine how Florida would have faired, in terms of opioid 
mortality rates, if they failed to implement the various legislative measures in 2010-2011. 
The results indicated the rate of prescription opioid overdose mortality may have been 
significantly lower, if Florida failed to enact various legislative measures, designed to 
curb prescription opioid use (Kennedy-Hendricks et al., 2016). 
Heroin. The opioid epidemic may have begun with the rapid prescribing of prescription 
opioids; however, as the epidemic ravaged on, the use of heroin has become a necessary 
topic of discussion.  
Heroin was first created in 1874, by a Bayer Pharmaceutical chemist, Heinrich 
Dreser (Quinones 2015). Initially, heroin was marketed as a non-addictive pain remedy. 
The claims of the non-addictive nature of the drug, coupled with the lack of available 
medicine, resulted in prevalent, widespread use and subsequent high rates of addiction 
(Quinones 2015). Around this time period, numerous government campaigns were 
conducted in an attempt to frame addicts as criminal in nature (Quinones 2015). Although 
the medical benefits of heroin were de-bunked, heroin soon became a staple on the illicit 
market.  Heroin was a dealers dream; cheap to make, easy to produce, and simple to 
traffic. Over time competition among dealers led to diluted products and discounted rates.   
In the 1970s, US Congressman, Robert Steele, analyzed the drug use reports of 
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U.S. military men during the Vietnam war (Frontline, 2014). Based on the analyzed 
reports, Steele concluded an addiction rate of 10-15% (Frontline, 2014). This finding 
together with the overwhelming amount of Vietnam soldiers who returned from war 
addicted to heroin, fast tracked the issue to President Nixon’s drug agenda.  In 1971, 
President Richard Nixon declared drugs, particularly heroin, to be the biggest enemy the 
Country faced (Gerstein and Green, 1993).  
Currently, you cannot listen to a news broadcast without hearing a discussion 
centering around the drug epidemic plaguing our nation. However, although heroin is a 
key part of the current epidemic, the using population is starkly different from that of the 
1970s (Cicero et al., 2014). Historically, heroin users were viewed as minorities living in 
low-income, primarily urban areas.  Currently, the stereotypical heroin user is an affluent 
Caucasian living in suburban or rural areas. The shift in the average heroin consumer 
may be attributed in part, to the increase in the use of prescription opioids and the 
subsequent transition from prescription opioids to heroin.  
Cicero et al. (2014) conducted a study in which they examined the transition from 
opioid use to heroin and vice versa. Of the participants who reported they began using 
opioids in the 1960s, at least 80% indicated their experimentation with opioid drugs, 
began with heroin (Cicero et al., 2014). When examining the participants who began 
using opioids in the 2000s, 75% reported their experimentation began with a prescription 
drug (Cicero et al., 2014).  Cicero et al., (2014) found the current wave of heroin users 
exhibit similar patterns of abuse as those individuals abusing prescription opioids. In that 
sense, the results indicated that prescription opioid users may shift to heroin at some 
point in their addiction. Numerous studies have demonstrated that heroin is easily 
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accessible and substantially more affordable than prescription opioids. This quote 
exemplifies the potential conundrum many prescription opioid users may face: 
All of my friends use heroin and I know multiple people who will sell it to me or 
help find me someone who has it. Also if I have money I wanna spend it on 
something I know will get me high. If I buy pills I might not have enough money 
to make sure I get high (Cicero et al., 2014, p. 825).  
 
In a study of 103 patients, derived from individuals entering drug treatment programs in 
the United States between 2009 and 2012, 47.4% reported using OxyContin, 30 days 
prior to the reformulation of OxyContin. Following the reformulation of OxyContin this 
number dropped to 30% (Moyer, 2013). In the same time frame, using the same study 
population, reports of heroin use practically doubled (Moyer, 2013). Although, there is 
not a clear line connecting the increase in heroin use to the crackdown on prescription pill 
mills and diversion, many argue this relationship is casual, at the very least.  
Prescription Opioids to Heroin. In 2014 the Deputy Attorney General, James M. Cole 
spoke at the “Pills to Needles: The Pathway to Rising Heroin Deaths” Event. Deputy 
Attorney General Cole stated the following in regards to the current opioid epidemic: 
Abuse of prescription drugs leads to dependency and that dependency leads to 
demand for more prescription drugs. That demand, users find, ultimately cannot 
be satisfied by the harder-to-obtain and more expensive prescription pills. That is 
where the heroin problems sneak in. The ready availability and lower cost of 
heroin makes it an easy and cheap alternative with tragic consequences 
(Department of Justice, 2014, p. 2).  
Deputy Attorney General James M. Cole stated the DEA revamped and increased efforts 
along the border to better address heroin trafficking. The amount of heroin seized along 
the southwest border skyrocketed 320% from 2008 to 2013. This statistic is reflective of 
both an increase in the attempt to traffic heroin across the border, as well as, the 
exhaustive efforts of the DEA to address the issue (Department of Justice, 2014).  
   
 
 
 
 
  
 
 
 
38 
 
 
 
 
 
 
In 2013, it was estimated that 681,000 individuals engaged in heroin use in the 
past year. This number represents an 82.6% increase from the data collected in 2007 
(Substance Abuse and Mental Health Services Administration [SAMHSA], 2014; Votaw 
et al., 2016). Notably, the 2017 NSDUH estimated 886,000 people had used heroin in 
2017. This number represents indicates a rise of over 200,000 people, from the data 
collected in 2013.  
Pain and addiction specialists have warned that by shutting down pill mills and 
eliminating the ability for prescription opioid users to access their prescriptions, we may 
see these users to turn to the illicit market to obtain opioids (Moyer, 2013). Heroin, being 
a cheaper and more available product on the illicit market, may serve as a substitute for 
prescription opioid users, in the event the user can no longer obtain or afford prescription 
opioids (Moyer, 2013). Nicholas Kardaras, PhD, stated prescription opioids and heroin 
cause the same neurochemical affect, which may entice prescription opioid users who are 
strapped for cash to seek heroin, a cheaper alternative (Moyer, 2013). Pain management 
specialist, Lynn Webster MD, relayed she had seen an increasingly high number of 
patients switch from prescription opioids such as OxyContin, to heroin after OxyContin 
was reformulated to prevent users from crushing and injecting (Moyer, 2013). 
From 2009-2012, many states enacted various legislative efforts designed to 
combat the diversion of prescription opioids. Although these efforts are often viewed as 
successful, in terms of reducing the amount of pain clinics and the illicit diversion of 
prescription opioids, many researchers argue these changes may have led to an increase 
in heroin and other easily accessible street drugs (Compton et al., 2016). The National 
Survey on Drug Use and Health (NSDUH) reported 79.5% of new heroin users, indicated 
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they had used a prescription opioid prior to heroin use (Dart et al., 2015). The CDC 
reported a slight decrease of opioid related deaths in 2012 and 2013; however, in 2014 
the number of opioid related deaths increased from 16,235 to 18,893 (Compton et al., 
2016). In 2014 the NSDUH projected that 917,000 people had engaged in heroin use 
during their life, this represents a 145% increase since 2007 (Compton et al., 2016). 
Additionally, there were 10,574 heroin related deaths in 2014, up from 1,842 in 2000 
(Compton et al., 2016). Muhuri et al. (2013) conducted a study utilizing data collected 
from the 2002-2011, NSDUH study. The results indicated a notable association between 
using pain relievers with no medical purpose (NMPR), and the use of heroin in the year 
following NMPR use (Muhuri et al., 2013). Muhuri et al. (2013) reported the initiation of 
heroin use was 19 times higher in individuals who reported using NMPR.   
Dart et al. (2015) conducted a study to examine diversion and abuse trends 
between 2002 and 2013, using five programs from the Research, Abuse, Diversion, and 
Addicted Related Surveillance System (RADARS).  Data from the National Poison Data 
System indicated heroin related deaths is inversely correlated with prescription opioid 
related deaths (Dart et al., 2015). Dart (2015) reported, heroin related deaths remained 
constant between 2002 and 2010; however, heroin related deaths increased, yearly, from 
2010 to 2013 (Dart et al., 2015). In contrast, prescription opioid related deaths spiked 
between 2002 and 2006, remained constant from 2006 to 2008, and then steadily 
decreased from 2010 to 2013 (Dart et al., 2015). The availability of prescription opioids 
began increasing in the 1990s and continued upward until a plateau in 2011. Dart et al 
(2015) reported findings, consistent with numerous other studies, which indicated an 
increase in the abuse of prescription opioids, prior to 2011.  
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According to the Drug Abuse Warning Network (DAWN), hospital medical 
emergencies associated with prescription opioids, increased 183% from 2004 to 2011 
(Dart et al., 2015; Drug Abuse Warning Network, 2013). However, recent trends indicate 
a decrease in the availability and subsequent diversion of prescription opioids. Dart et al 
(2015) attributes this reduction to various legislative measures and an associated decrease 
in prescription pill mills, etc. Notably, although the direct cause may be unknown, this 
study demonstrates the fluctuation of the rate of opioid and opioid analgesics abuse is 
correlated with rises in heroin related deaths (Dart et al., 2015). 
Peavy et al. (2012) conducted a study in which they interviewed 553 syringe-
exchange clients, of which 433 admitted to using heroin in the four months prior to the 
interview. Of these participants, 39% reported using some sort of prescription opioid 
prior to experimenting with heroin (Peavy et al., 2012). These participants were typically 
younger, Caucasian, and appeared to have a more stable living situation. These results 
can have a variety of implications for the trajectory of drug use in the United States in the 
past decade. For one, the indication that those individuals who reported using prescription 
opioids prior to heroin were generally younger than the alternative may be a result of the 
availability of prescription opioids through both licit and illicit channels. This notion 
would be in line with the argument that prescription opioid non-medical use may be a 
gateway to heroin use.  
Similar effects, different chemical makeup 
Imagine its 2005, you went to a doctor for a knee injury and left with a two-month 
supply of oxycodone. Two-months later you have gone through your supply, but can’t 
see to shake the headache, fever, nausea, etc. Your knee may not hurt anymore, but the 
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withdrawal symptoms are too much to bear. You decide to revisit the doctor, upon arrival 
you present the receptionist with the $200 “doctor fee” and your ushered to a crowded 
waiting room, filled with people from all walks of life. Three hours later your name is 
called, you are directed to a room where you will spend the next 2 minutes chatting with 
a doctor about your lingering knee pain. You managed to “convince” the doctor of your 
dire pain, and in turn received a 90-day supply of 60mg of OxyContin. However, one pill 
at a time is no longer satisfying the craving, you begin doubling and tripling the dosage, 
and before long your down to your last pill, 20 days early. You know you cannot visit the 
same doctor, so you find an ad in the paper for “pain management clinics, with onsite 
pharmacy” you even find a coupon in the paper for one free visit. Very similar to the first 
doctor you spend a total of 5 minutes with the doctor and leave with another 90-day 
supply of oxycodone.  
Fast forward to 2012, virtually every fraudulent pain management clinic in 
Florida is shutdown; the ones in operation are mandated by very stringent guidelines; 
additionally, there’s a database which tracks all of the prescriptions and works to prevent 
doctor shopping. Many prescription opioid users were no longer able to obtain these 
medications through legal channels. As a result, they turned to illicit networks to obtain 
opioids and satisfy the craving. However, as more pill mills were shutdown, street dealers 
were finding it increasingly difficult to acquire prescription opioids. As any instance of 
supply and demand, as the demand increased, the price followed in suit. Countless users 
were unable to afford the amount of prescription opioids which would satisfy their 
craving. At this point, many addicts were simply trying to fight off the feelings of 
withdrawal, getting high was no longer an option.  Users who may have started for 
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medical reasons, were now meeting dealers on street corners to get a baggie of heroin. 
Users who failed to realize they had developed an addiction, were now injecting drugs in 
to any viable port to achieve a stronger, faster, better high.  
 Addiction, in itself, is a horrible, horrible thing to endure. However, addiction to 
a legally distributed medical prescription is arguably safer, than addiction to heroin, 
crack, or any other substance sold through illicit networks. For one, many heroin users 
choose to inject the drug, injection opens the door to the various infectious diseases 
associated with needle sharing. Secondly, and perhaps most notably, is the fact that 
dealers, users, medical professionals, etc. are completely in the dark as to the makeup of 
the purchased substance. One may think they are purchasing pure heroin, when in fact, 
this heroin may have been mixed or cut with a different substance. Users, dealers, first 
responders, are all in the dark as to the chemical makeup of each “batch” of heroin, as 
each is different, it makes it difficult for users to determine how much they need to use to 
obtain the high but avoid the overdose. Additionally, first responders may have difficulty 
determining how to address the medical emergency due to the unknown components.  
Synthetic Opioids 
Synthetic opioids and natural opioids are similar in that they target the same 
receptors. However, natural opioids are naturally occurring substances, whereas, 
synthetic opioids are synthesized in a laboratory (DEA, 2017). Synthetic opioids are 
cheaper to produce and easier to acquire than natural and semi-synthetic opioids, such as 
heroin. As a result, many street dealers mix synthetic opioids with heroin, in order to 
increase profits. Often times, synthetic opioids are clandestinely produced as counterfeit 
prescription opioids, such as OxyContin (DEA, 2017). The abuse pattern of synthetic 
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opioids is very similar to heroin and prescription opioids (DEA, 2017). However, 
synthetic opioids are extremely and often fatally, potent. Consumers are unable to 
determine the potency of a clandestinely produced synthetic opioid, which heightens the 
risk of overdose (DEA, 2017). Prekupec et al (2017) stated there were 9,580 deaths 
attributed to synthetic opioids, excluding methadone, in 2015. Recently collected law 
enforcement data demonstrated a surge in the street presence of novel synthetic opioids 
(NSOs), including but not limited to: acetyl fentanyl, butyrylfentanyl, furanylfentanyl, 
and U-47700 (Prekupec et al., 2017).  
 Organized crime groups identified the potential profit in the drug trade and have 
spent recent decades infiltrating the marketplace. In order to stay one step ahead of law 
enforcement, organized crime groups have partnered with drug manufacturers located 
primarily in China to benefit from the manufacturing capability in Asian countries 
(Prekupec et al., 2017). As the United States government works to designate new illicit 
substances as illegal, manufacturers are developing analogues of these substances, to 
serve as a replacement (Prekupec et al., 2017). Recent estimations indicate hundreds of 
thousands of counterfeit prescription pills can be manufactured from just one kilogram of 
new psychoactive substances (NPS), such as fentanyl analogs (Prekupec et al., 2017). 
These tablets can be purchased online and imported through international delivery 
services and the US mail. The small quantities of each shipment makes it extremely 
difficult for mail inspectors and law enforcement officers to identify and seize the 
packages (Prekupec et al., 2017).   
  As China continues to create fentanyl analogs, U.S. law enforcement agencies 
and subject matter experts struggle to stay up to date with the latest trends and 
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substances. In order for scientists and toxicologists to determine the chemical 
composition of each new analog, the substance must be identified and confiscated by law 
enforcement and quantified in the seized drugs (Prekupec et al., 2017). Biological 
samples from those individuals who ingested the substance, can be used for testing. 
Notably, a standard urine toxicology screen can detect heroin and morphine, but is unable 
to identify opioids with unique structures, such as fentanyl and fentanyl analogs 
(Prekupec et al., 2017). Prekupec et al. (2017) explained fentanyl can be identified using 
an enzyme-linked immunosorbent assay (ELISA). However, more complex methods are 
needed in order to differentiate between fentanyl and fentanyl analogs (Prekupec et al., 
2017). Prekupec et al. (2017) stated “to date, no antibody-based methods are 
commercially available to detect non-fentanyl analogs such as AH-7921, U-47700, or 
MT-45.” It has become extremely difficult to develop immunoassays for all NSOs, at the 
rate of which they are created. With that said, it is suggested the frequency of NSO use is 
likely underreported.  
U-47700 "Pink". U-47700, commonly referred to as "pink" is a synthetic opioid. In 
November 2016, the DEA officially classified U-47700 as a Schedule I drug, which 
means it offers no medical benefit but yields strong potential for addiction. The National 
Forensic Laboratory Information System (NFLIS) indicated the first report of U-47700 
occurred in October 2015 (DEA 440, 2016). The DEA reported based on the collected 
evidence, the consumption pattern of U-47700 mirrors heroin and prescription opioids 
(DEA 440, 2016). Recent seizures identified U-47700 in tablet form, designed to appear 
as a pharmaceutical opioid or stamped with logos to mimic heroin (DEA 440 2016). 
Reports indicate U-47700 has been identified as a solitary substance as well as mixed 
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with various substances such as heroin, fentanyl and fentanyl analogs (DEA 440, 2016). 
The majority of U-47700 is distributed through online channels or street dealers. Due to 
the fact that this substance is distributed through non-regulated sources, the user is unable 
to determine the true chemical make-up of the substance. This puts the user in grave 
danger of overdosing, etc. Currently, U-47700 is advertised through various online 
channels as a "research chemical" (DEA 440, 2016). The DEA identified at least 46, U-
47700 related fatalities from late 2015 to mid 2016 (DEA 440, 2016).  
It is important to note; reporting of occurrences of U-47700 was not specifically 
requested by the Florida Medical Examiners Commission in 2017. Due to the rapid rise 
of deaths associated with U-47700, many Florida Medical Examiner Districts voluntarily 
reported data; however, the data is not complete. A total of 132 medical examiner 
occurrences of U-47700 were reported in Florida during 2017. Reporting of U-47700 by 
all districts will begin with the 2018 Drugs Identified in Deceased Persons Reports.   
Fentanyl. In the 1960s Janssen Pharmaceuticals manufactured a synthetic opioid, now 
referred to as fentanyl (Lozier et al., 2015). The CDC (2017) defines Fentanyl as a 
"synthetic and short-acting opioid analgesic", typically prescribed for patients diagnosed 
with advanced forms of cancer. The potency of Fentanyl makes it incredibly dangerous. 
In some cases, ingestion of only .25 mg can be fatal. Notably, a dose of fentanyl can be 
up to 100 times more potent than morphine and 30-50 times stronger than heroin. (CDC, 
2017; DEA, 2015).  In order to meet the ever-rising heroin demand, dealers have been 
found to use illicitly manufactured fentanyl (IMF) or a fentanyl analog to mix with heroin 
and meet the demand, without diminishing the potency (Bode et al., 2017).  
In the 1970s clandestine laboratories began to synthesize fentanyl derivatives, 
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these analogs were comparable in pharmacokinetics but differed in potency (Lozier et al., 
2015). Lozier et al. (2015) stated in the early 1980s, IMF and fentanyl analogs were 
flooding the illicit channels. Misaildi et al. (2017) reported over 1400 fentanyl analogues 
have been manufactured in the recent decades, of which, 200 have been studied by 
pharmacologists, and 12 have been identified in the illicit drug market in the last five 
years.  In the recent decades, we have seen several waves of fentanyl related overdoses 
throughout the Country (Lozier et al., 2015). In 2013, as a result of fentanyl seizures, the 
NFLIS identified 942 fentanyl submissions (DEA, 2015).  The following year, this 
number increased to, 3,344 (DEA, 2015). Traces of fentanyl were identified in 90% of 
the 281 accidental overdoses which occurred in Ohio, during a two-month period in early 
2017 (Morgan & Jones, 2018).  
 The DEA stresses the importance of differentiating between pharmaceutical 
fentanyl and illicitly manufactured fentanyl (IMF). Although the diversion of prescription 
fentanyl is certainly a factor, the drastic increase in fentanyl related overdose deaths can 
primarily be attributed to IMF (DEA, 2016a). Prekupec et al. (2017) stated, the number of 
overdose deaths involving synthetic opioids may be grossly underreported.  Typically, 
medical examiners and crime laboratories do not conduct testing to determine the 
presence of fentanyl or NSOs, unless instructed to do so. As a result, overdoses which 
may be solely attributed to heroin, may be mischaracterized.  
Not only is Fentanyl extremely potent, but it is also easy to acquire through the 
dark web or tor browser and significantly more profitable than heroin (Kulbarsh, 2016).  
In the time period between 2010 and 2014, heroin involved deaths skyrocketed increasing 
more than three-fold (Macmadu et al., 2017; Compton et al., 2016). Additionally, from 
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2013 to 2014, synthetic opioid related overdoses increased 80% (Macmadu et al., 2017; 
Rudd et al., 2016).   
Gladden et al., (2016) found when purchasing drugs through illicit channels, the 
user is typically unaware of the chemical make-up of the substance. Therefore, it is 
difficult for a user to gauge how much he/she must inject in order to achieve the high but 
avoid the overdoses. Drug purchasers who unknowingly purchase products, laced or cut, 
with fentanyl are at a heightened risk of overdosing, due to the intense potency of 
fentanyl. Macamadu et al. (2017) conducted a study to examine the use of fentanyl 
among young adults who reported non-medical prescription opioid use, in the United 
States. Of the participants who reported using Fentanyl in the six-month study period, 
59% admitted being unaware that they were using fentanyl, until after consumption. 
Unanimously, the participants recognized the potential overdose danger of using fentanyl 
(Macamadu et al., 2017).  
The Florida Department of Law Enforcement Medical Examiners Commission 
Annual Report, reported 251 deceased individuals were found to have fentanyl in their 
system, in 2012 (DEA Fentanyl, 2016). This number increased 263% to 911 in 2015 
(DEA Fentanyl, 2016). In 77.4% of the cases identified in 2015, fentanyl was determined 
to be the cause of death.  This represents a 418% increase from the data collected in 2012 
(DEA Fentanyl, 2016). From 2013 to 2014, fentanyl submission in Florida, jumped 494% 
from 33 to 196 (CDC, 2016). In the same time period, Florida experienced a 115% 
increase in fentanyl related deaths, which totaled 397 fentanyl related deaths (Gladden et 
al., 2016). In the period between January and June 2015, fentanyl analogs (acetyl 
fentanyl, butyryl fentanyl and beta-hydroxthiofentanyl) were identified in 49 lethal drug, 
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overdoses (Gladden et al., 2016).  Gladden et al. (2016) identified additional substances 
present in the wake of a lethal fentanyl overdose. In 2013 to 2014, 33% of fentanyl deaths 
tested positive for cocaine, 19% tested positive for heroin, and 28% tested positive 
morphine (Gladden et al., 2016).  
It is important to note, heroin quickly metabolizes to morphine, therefore it is 
possible that morphine positive fentanyl deaths, could be attributed to the metabolism of 
heroin (Harruff et al., 2015). The detection of other illicit substances present in the case 
of a fentanyl overdose provides support for the notion that illicitly manufactured fentanyl 
is likely to blame.  The dramatic increase in fentanyl related deaths demonstrates the high 
potency of fentanyl and the danger of engaging in IMF use. Notably, most recreational 
and habitual drug users are often unaware the heroin, or other illicit substance they are 
purchasing may be mixed with fentanyl or a fentanyl analog.  
Acetyl Fentanyl. Acetyl fentanyl is a synthetic opioid, derived from fentanyl. The 
chemical composition of acetyl fentanyl may be similar to fentanyl; however, the DEA 
classified acetyl fentanyl as a schedule 1 substance, with no medical use (Stogner, 2014). 
Although acetyl fentanyl has been linked to a slew of overdoses in the recent years, it is 
possible that many deaths and overdoses associated with acetyl fentanyl are deemed 
heroin related, due to the absence of testing to further identify the chemical make-up 
(Stogner, 2014). Stogner (2014) stated in the case of an overdose, patients would likely 
respond similarly to naloxone, as in a heroin overdose; however, a stronger dosage would 
likely be needed.  
In 2014 drug traffickers were exploiting a grave weakness in the war against 
drugs. At this time, acetyl fentanyl was not scheduled under the Controlled Substance 
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Act. The fact that it was a fentanyl analog made it illicit for human consumption; yet, if 
the packaging indicated the contents were not for human consumption, it would be 
difficult to seize and subsequently prosecute (Stogner, 2014). Stogner (2014) referred to 
this conundrum as the “analogue loophole”. It is important to note, in July 2015, Acetyl 
fentanyl officially became classified as a schedule 1 substance. However, the “analogue 
loophole” is still very problematic due to the vast efforts of clandestine drug 
manufactures to create new analogs, and inundate the marketplace, before law 
enforcement can identify the new products.  
In order to keep buyers content and increase profits, dealers may mix a small 
amount of heroin with a dose of acetyl fentanyl and market the product as pure heroin. 
This allows the dealer to use less heroin, a more expensive and harder to traffic product. 
Stogner (2014) mentioned acetyl fentanyl may be manufactured and packaged to imitate 
prescription pills, typically oxycodone. Stogner (2014) stated analogues of schedule 1 
substances have been marketed as products such as cleaners and plant food and sold in 
various drug paraphernalia stores.  
Butyrylfentanyl. Butyrylfentanyl, a fentanyl analog, was first discussed in scientific 
journalism in the 1980s. NFLIS reported the first confiscation of Butyryfentanyl occurred 
in March 2014 in Kansas (Prekupec et al., 2017). As of 2015, the DEA attributed 
Butyryfentanyl to at least 40 deaths (Prekupec 2017). The DEA stated the potency and 
toxicity of Butyryfentanyl is unknown due to the lack of scientific data (DEA, 2016a). 
However, the pharma logical profile is similar to that of fentanyl and other fentanyl 
derivatives. Additionally, the abuse pattern of this substance is similar to heroin, fentanyl, 
and other fentanyl analogs. In May 2016, Butyryfentanyl was temporarily placed in to 
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schedule 1, of the schedules of controlled substances.  The final order stated, the 
substance offered no medical value and serves as a danger to users and first responders, 
due to the clandestine production (DEA, 2016a). 
Furanylfentanyl. Furanylfentanyl, a fentanyl analog, was first mentioned in a patent text 
in 1986 (Prekupec et al., 2017). There is limited knowledge as to the potency and toxicity 
of this substance, due to the lack of human testing.  Furanylfentanyl was first noted by 
NFLIS in January 2016 (DEA, 2016e). In the time period between January 2016 and May 
2016, 80 law enforcement reports noted the confiscation of identification of 
Furanylfentanyl (DEA, 2016c). DEA (2016e) identified at least 128 Furanylfentanyl 
related deaths in 2015 and 2016. Due to the lack of medical value and the potential for 
addiction and overdose, in September 2016, Furanylfentanyl was temporarily placed in to 
schedule 1, of the schedules of controlled substances (DEA, 2016e). 
Carfentanil. Carfentanil is a synthetic opioid designed to tranquilize elephants and other 
large mammals (DEA, 2016c). Carfentanil is a derivative of fentanyl; however, it is 100 
times more potent than fentanyl, and 10,000 times more potent than morphine (DEA, 
2016c). Due to the lack of human testing, experts are unsure of the lethal human dose of 
Carfentanil. In 2015, the United States produced 19 grams of Carfentanil for legitimate 
purposes (Melendez, 2016). In 2016, the DEA identified one shipment from that 
contained more than 50 times that amount (Melendez, 2016). US Customs and Border 
Patrol reported 5 Carfentanil seizures between October 22, 2016 and June 27, 2017 (US 
Customs and Border Protection Office of Field Operations, 2017).  The amount of 
Carfentanil seized in these shipments totaled nearly 2 kilograms (US Customs and Border 
Protection Office of Field Operations, 2017). 
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The DEA reported Carfentanil is typically trafficked from Mexico and China and 
sold directly in to the illicit drug market, often through the dark web. Similar to fentanyl, 
Carfentanil is cheap to produce and easy to acquire. The potency of the drug, allows 
dealers to mix it with heroin to keep cost down and make a bigger profit. Notably, 
because Carfentanil is extremely potent, less quantities are necessary for trafficking 
purposes. Therefore, it is easier to send and disguise through mail channels. 
The DEA reported overdose rates skyrocketed in August and September 2016. 
The Midwest and Appalachian regions seemed to be hit the hardest (Sanburn, 2016). 
Hamilton County, Ohio reported 200 overdoses in a seven-day period in August 2016 
(Sanburn, 2016). The DEA estimated the Midwest region saw about 300 overdoses in 
less than a month. Tom Synan, the director of the Hamilton County Heroin Coalition, 
hypothesized the Carfentanil originated in China and travelled to Mexico in response to 
online purchases. Mexican drug traffickers then transported the product to the United 
States and distributed via illicit channels (Sanburn, 2016).   
Misailidi et al. (2017) stated that up until March 2017 Carfentanil was not 
regulated in China, therefore there was no limitation on the production, manufacturing, or 
sale. Misailidi et al. (2017) explained Carfentanil is openly marketed on the dark web, 
typically as a “research chemical”. In 2016, a search in a dark web search engine, yielded 
118 websites in which Carfentanil was available to purchase (Misailidi et al., 2017). 
Melendez (2016) quoted one dark web vendor who warned potential consumers of the 
potency of Carfentanil “Again, we can’t stress this enough, Carfentanil is meant to be 
purchased by *only* experienced fentanyl users with a high tolerance, this stuff is NO 
JOKE.” 
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Cryptomarkets. Unbeknownst to many, the dark web aka the deep web is an online 
platform which allows users anonymity. The dark web allows users to anonymously 
purchase items such as guns, ammunition, etc. using bitcoin. Bitcoin is a digital currency 
which operates independently of a central bank and utilizes various encryption methods 
to ensure anonymity (Yellin et al., n.d.). Gilbert and Dasgupta (2017) defined a 
cryptomarket as an online, internet-based platform which allows users to operate under 
false personas to conduct transactions for various information and commodities. The 
privacy of the dark web coupled with the anonymity of the bitcoin, created the ultimate 
market for drugs. Perhaps one of the most popular cryptomarkets, prior to its 2013 
shutdown, was Silk Road (Gilbert and Dasgupta, 2017). Silk Road, created in February 
2011, flourished for two years before eventually being shutdown as the result of an FBI 
investigation. Once Silk Road was shutdown, cryptomarkets began to multiply due to the 
potential profit and the open market. Gilbert and Dasgupta (2017) estimated in early 
2017, about 50 cryptomarkets were in operation.   
Although numerous cryptomarkets popped up after the Silk Road shutdown, 
Alphabay appeared to be the most profitable. Similar to Silk Road, Alphabay was an 
online marketplace, located in the deep web, designed to facilitate anonymous 
transactions between users. According to the FBI, Alphabay became operational in 
December 2014 (FBI, 2017). It took several months to gain the trust and support of the 
dark web marketplace; however, within six months Alphabay was flourishing (FBI, 
2017). At the time of the shutdown, Alphabay had over 200,000 users, 40,000 vendors 
and 250,000 drug products and toxic chemicals listed for sale (FBI, 2017).  To put this in 
comparison, in 2013, when Silk Road was shut down in 2013, it had about 14,000 listings 
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for illicit drug products (FBI, 2017). The number of vendors advertising for heroin and 
fentanyl was 238 and 122, respectively (FBI, 2017).  From inception to closure, 
Alphabay generated over $1 billion in illicit transactions (FBI, 2017). 
Some, including the attorney of Dread Pirate Roberts, aka Ross Ulbricht, the 
founder of silk road, argued that Silk Road provided a “safe” environment for drug users 
to purchase products. Essentially the argument holds that Silk Road eliminated the drug 
dealer/drug user relationship. As a result, drug users were provided an avenue to purchase 
drugs, without travelling to a bad area of town, establishing connections with drug 
dealers, etc. However, the counterargument holds, silk road and other cryptomarkets 
result in the “amazon” effect. Essentially, the ease of purchase appeals to the consumer. 
Law enforcement professionals argue many cryptomarket customers, may have never 
purchased a drug if it wasn’t for the cloak of anonymity “guaranteed” through the use of 
TOR and bitcoin.  
Barratt et al. (2016) conducted an ethnographic study with 17 individuals who 
reported purchasing drugs on Silk Road, the results indicated that at least “some” of the 
study population admitted Silk Road was the start of their drug use. One participant 
explained that he had no avenues to purchase drugs, prior to the establishment of the Silk 
Road (Barratt et al., 2016).  14 of the 17 participants indicated an immediate increase in 
drug use, following the first purchase from Silk Road (Barratt et al., 2016). Notably, 
several participants reported their drug use “steadied” after the initial excitement (Barratt 
et al., 2016). The majority of the participants reported finding a new cryptomarket 
following the closure of Silk Road.  
Quintana et al. (2017) conducted a study in 2015, in which they sent four samples, 
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marketed in a cryptomarket on the dark web as heroin to Energy Control for evaluation. 
The results indicated that each of the four samples contained products other than heroin. 
All four of the samples were found to contain Ocfentanil, a synthetic opioid derived from 
fentanyl. A test conducted using lab rates yielded Ocfentanil is about 2.5 times more 
potent than fentanyl and 1,300 times more potent than morphine (Blanckaert, 2017). As 
with other fentanyl analogs, Ocfentanil is dangerously more potent than heroin.  
Products marketed as heroin, which contain fentanyl analogs, are extremely 
dangerous to users due to the increased potency. Proponents of cryptomarkets argue the 
substances offered are typically pure and potent, as a result of the rating scale. “Dealers” 
are concerned with their rating, so they are sure to be honest about the product they are 
marketing. However, this study demonstrates that substances sold on the dark web may 
not always be pure and could be cut or mixed with other substances.  
Naloxone 
The first part of this literature review was provided to demonstrate the prevalence, 
rapid expansion, and danger of the opioid epidemic in the United States. The remainder 
of this literature review will examine the current, available literature pertaining to the use 
of naloxone. The difference between getting an opioid from a trusted source such a 
doctor and getting an opioid through a variety of illicit channels such as a street dealer or 
dark web, can be the difference between life and death. As the number of overdoses 
continues to skyrocket and China continues to infiltrate the drug market with synthetic 
opioids, the need for naloxone is stronger than ever.  
Substance Abuse and Mental Health Services Administration (SAMHSA) 
explained Naloxone is an FDA approved medication, used to prevent opioid overdoses. 
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In the midst of a drug overdose, naloxone is often used as a last ditch effort to block the 
opioid receptor sites and ideally stop and reverse the respiratory damaging effects of an 
overdose (SAMHSA Naloxone, 2016).  
Fairbairn et al. (2017) explained there are four naloxone delivery methods that are 
currently on the market. These methods include: intramuscular via vial, intramuscular via 
auto injector (Evzio), multi-step off-label intranasal spray, and a single-step nasal spray 
(Narcan®) (Fairbairn et al., 2017).  Resnick (2014) quoted a fire official who stated 
“there’s somebody who’s on the ground, who’s literally dead, sometimes they’re blue, 
sometimes they’re black, and you administer this stuff and sometimes in a minute or two 
or three they’re actually up and talking to you” (p. 1).  
 In 2014, 47,055 fatal drug overdoses occurred in the United States, 61% (28,647) 
of which were attributed to prescription opioid analgesics and heroin (FDA, 2016). The 
FDA (2016) explained the pathophysiology and critical response time of an overdose 
attributed to a legally obtained prescription opioid is comparable to an overdose which 
occurs as a result of an illegally obtained opioid. Simplistically speaking, regardless of 
where/how the opioid is obtained, the response to an overdose will be the same. Boyer 
(2012) explained higher doses of opioids can cause respiratory depression to occur which 
affects the oxygenation of blood, this can lead to a reduction of oxygen for the brain and 
the heart (Boyer 2012, FDA, 2016). The deprivation of oxygen from the heart and the 
brain will eventually result in death (FDA, 2016). In most cases, respiratory depression 
can take up to 3 hours, and it can be reversed until mortality (Boyer 2012). Naloxone is 
used in the wake of an overdose to reverse respiratory depression by “displacing opioids 
from the opioid receptor and block the binding of additional opioids for 20 to 90 
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minutes” (Boyer, 2012). Notably, depending on the amount and type of opiate injected, 
the user may reenter respiratory depression after the application of naloxone. 
 Although naloxone is currently the ‘talk of the town’ and debated, the use of 
naloxone is not new, by any means. In the late 1990s, amidst the ‘heroin era’, syringe 
needle access programs (SNAP) were initiated in cities such as New York to reduce the 
impact of sharing syringes linked to HIV and other infectious disease transmission. 
Fairbairn et al. (2017) explained community based programs partnered with SNAP and 
began dispensing naloxone to drug users, specifically those who inject drugs. These 
programs were found to be very successful in reducing heroin-related deaths.  
Walley et al. (2013) conducted a study in which they compared the opioid 
overdose death rates in communities where overdose education and nasal naloxone 
distribution (OEND) was implemented to communities with no OEND programs. 
Communities where OEND was implemented saw a decrease in opioid overdose death 
rates.  Notably, there are myriad of other factors that could have impacted the reduction 
in opioid overdose deaths. However, this study adds support for the importance of 
community education and the potential positive effects of distributing naloxone.  
 Fairbairn et al. (2017) stated in 2010 the United States saw a dramatic increase in 
the heroin overdose rates. During the same time period, the U.S. saw a decrease in the 
number of opioid prescriptions supplemented by an increase in the production of 
synthetic opioids. Although heroin overdoses are apparent and problematic, the current 
crisis is more complex than the heroin era of the 1990s. Fentanyl, fentanyl analogs, and 
other clandestinely produced synthetic opioids are flooding the drug marketplace. The 
potency of these alternative substances have had a devastating effect. Heroin users have 
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always ‘gambled’ with the purity/potency factor which is considered an overdose risk; 
however, synthetic opioids drastically increase the risk of overdose. 
The optimal dosage of naloxone depends on the amount of the substance 
injected/ingested as well as the potency of the substance. This has proven extremely 
problematic in the current drug climate. Recent studies have found that a fentanyl 
overdose may require multiple doses of naloxone to reverse the overdose (Somerville et 
al., 2017; Sutter et al., 2017; Fairbairn et al., 2017). This was demonstrated in British 
Columbia, Canada in 2016. According to medical professionals and first responders, 
patients who reported smoking crack-cocaine, which was later determined to be furanyl-
fentanyl, required notably high dosages of naloxone (Klar et al., 2016).  Several patients 
required 3.0 mg of injectable naloxone, which is more than 7 times the typical dosage of 
0.4 mg.  Klar et al., 2016)  
In 2014, the World Health Organization (2014) suggested individuals who have a 
strong chance of being present at the time of an opioid overdose should carry naloxone 
(WHO, 2014). As opioid overdoses continue to ravage the United States, the need to 
educate users and the community on how to react in case of an overdose has become 
increasingly apparent.  It is customary for medical facilities which administer opioid 
medication, to carry naloxone. Additionally, ambulances and other medical transportation 
systems are typically equipped with naloxone. However, many argue it makes the most 
sense to equip addicts and family members with naloxone, which will allow them to 
respond quickly in the event of an overdose.  From the early 1990s to present day we 
have seen a notable increase in the programs designed to educate and equip individuals 
with the tools to effectively handle an opioid overdose.  
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The Harm Reduction Coalition (HRC), conducted a study in which they sought to 
identify how many naloxone kits had been distributed as of June 2014. They contacted, 
through online survey, executives of 140 organizations which distribute naloxone kits. 
Such organizations included pharmacies, health care providers, rehabilitation facilities, 
etc. (Wheeler et al., 2015). Wheeler et al. (2015) reported from 1996 to June 2014, the 
136 responding organizations, provided 152,283 individuals with applicable training and 
overdose kits which include naloxone. Of the 136 responding agencies, 109 collected 
overdose metrics, these agencies documented 26,463 overdoses reversals, 8,000 of which 
occurred in 2013 (Wheeler et al., 2015).  
The Legal Journey. Naloxone is characterized as a prescription drug; however, it is not 
classified as a controlled substance. (van Dorp et al., 2007). Although classified as a 
prescription drug, naloxone has no potential for abuse and a low overall risk of harm 
(Davis and Carr, 2017). In the recent years, we have seen a push by both the Federal and 
State government to expand the access to naloxone in order to better equip laypersons. 
However, numerous overdoses which have resulted in death are often viewed as 
preventable if naloxone was on hand for immediate application. Naloxone can be an 
extremely powerful, life saving tool; however, it is extremely important that it is 
administered as soon as possible to avoid permanent cell death and other possible 
negative effects.  Time is of extreme importance when it comes to opioid over-induced 
respiratory depression.  
Due to the impeding clock and the prevalence of overdoses, numerous medical 
health associations advocate for the importance of equipping lay persons and addicts with 
take-home naloxone kits (Davis and Carr, 2017). However, even though naloxone is not a 
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controlled substance, it is defined as a prescription substance and therefore typically 
requires the prescriber to examine the individual seeking the prescription, prior to writing 
the prescription (Davis and Carr, 2017). Nevertheless, given the current state of the 
opioid epidemic, in the recent years’ numerous states have adjusted the stringent 
guidelines which prevented widespread naloxone distribution.  
Davis and Carr (2017) explained the majority of states have disregarded the 
constraint which required naloxone to be administered only for use on an individual for 
which the prescribing doctor had an established prescriber-patient relationship. In 44 
states, third-party prescription laws allow naloxone to be prescribed and distributed to 
any individual who may be present at the time of an overdose (Davis and Carr, 2017). 
Alternative means of distribution occur via non-patient specific standing orders (NPS). 
These orders are typically written to allow the distribution of naloxone to any individual 
at risk of an overdose (Davis and Carr, 2017). NPS orders fall widely under the best 
judgment of the prescriber. Furthermore, in the recent years 32 states have enacted 
legislation which provide naloxone prescribers with criminal immunity for “state law 
violations to pharmacists that dispense naloxone as authorized by the law” (Davis and 
Carr, 2017, p. 183). The majority of states have removed some of the legal barriers to the 
prescribing and dispense of naloxone.  
Good Samaritan Laws. As mentioned above, time is of the essence when it comes to 
responding to an opioid overdose. With a product such as naloxone available, one may 
assume that the majority of opioid overdoses may be preventable. However, often times, 
the individuals who witness the overdoses are in the possession of drug paraphernalia, 
under the influence of an illegal substance, or simply at the wrong place/wrong time and 
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concerned of how they may be treated in light of law enforcement intervention. These 
fears have prevented countless of individuals from contacting the authorities in the wake 
of an overdose and may have delayed a potential life saving effort.   
Based on information reviewed, in July 2017 40 states and the District of 
Columbia were found to have enacted Good Samaritan legislation (Davis, 2017). 
Although the inner workings of each law differs by state, overall the legislation is 
designed to offer individuals who in good faith contact authorities in the wake of an 
overdose, some sort of protection.  Depending on the state, Good Samaritans may be 
granted protection from possession of drug paraphernalia or illicit substances, as well as 
protection from probation or parole violations, and various other charges.  
Price and Products. Naloxone was first approved by the FDA in 1971 (Gupta et al., 
2016). The rapid and widespread increased in opioid overdoses led to the formulation of 
the auto-injector formula (Evzio®) (Gupta et al., 2016). In 2014, the FDA accelerated the 
approval process to meet the ever growing demand for a user friendly naloxone delivery 
method (Gupta et al., 2016). The auto-injector formula allowed individuals with no 
medical training an easier route to deliver naloxone.  
In 2015, the FDA again accelerated the approval process, for a nasal-spray 
product designed to deliver naloxone. The nasal-spray also known as naloxone was 
designed to reduce the risk of administering naloxone, by the untrained professional. As 
the theory of supply and demand would indicate, in the recent years we have seen steep 
increases in the cost of naloxone.  Perhaps most significantly, Evzio®, the auto-injector 
version of naloxone increased from $690.00 in 2014 to $4,500 in 2016 (Gupta et al., 
2016).  
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Recent data indicate two nasal-spray doses of naloxone costs approximately $178 
for government agencies, first responders, health departments, and other qualifying 
groups when they purchase directly from the manufacturer, Kaléo, or its authorized 
distributors (Evzio, 2018). The lack of competition in the marketplace coupled with the 
growing demand, allows retailers to continually raise prices. In the recent years, states 
such as California and Vermont have enacted legislation designed to prevent unnecessary 
price gouging (Gupta et al., 2016).   
Childs (2015) listed several road blocks that law enforcement agencies may face 
in the implementation of naloxone policies. The first and perhaps most notable is the ever 
increasing price of naloxone. The gravity of the potential expenses associated with 
equipping law enforcement with naloxone has resulted in back lash from the law 
enforcement community. Law enforcement agencies maintain they do not have the 
funding available to implement naloxone programs which require purchasing naloxone 
and ensuring officers are trained to properly administer the medication. Although there 
are cheaper versions of naloxone available, such as the syringe based formula, law 
enforcement officers in certain states are not authorized to administer the medication 
through injection, which limits the purchasing options (Childs, 2015).  
 The argument against the price of naloxone has continued to strengthen due to 
the continuous emergence of synthetic opioids. Synthetic opioids such as fentanyl, and 
fentanyl analogs have been found to require a stronger dose of naloxone.  In the past the 
starting dosage of naloxone was recommended to be .4 mg; however, in the recent years 
it has been recommended to immediately start with a 2.0 mg dose (Prekupec et al., 2017). 
Prekupec et al. (2017) stated there are known cases which have required 10mg to 20 mg 
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doses of naloxone.  
Additional barriers to law enforcement implementation of naloxone policies 
include liability concerns, lack of Good Samaritan laws, and medical doctors who refuse 
to write a standing order for the dispense of the naloxone (Childs, 2015). Due to the fact 
that naloxone is a prescription medication, but not a controlled substance, first responders 
must be authorized to carry and administer the drug (BJANTTAC, n.d.). Typically, a 
licensed prescriber can issue a “standing order” to an entire department which would 
allow first responders to carry and administer naloxone (BJANTTAC, n.d.).  
Commonly, the law enforcement agency and the collaborating health care agency 
sign a memorandum of agreement to legitimize the relationship (BJANTTAC, n.d.). New 
York was the first state to work directly with the Board of Pharmacy to simplify the 
process and enacted legislation which allows law enforcement agencies to purchase 
naloxone directly from a wholesaler, which eliminates the need for a prescription and a 
standing order (BJANTTAC, n.d.). In some states, law enforcement agencies have 
established working relationships with EMS agencies to streamline naloxone training and 
purchasing (BJANTTAC, n.d.).  
Adversaries of Naloxone. Many adversaries of naloxone distribution programs argue 
that by distributing naloxone kits to addicts, family members, and friends, we are 
essentially enabling addicts to abuse illicit drugs.  Seal et al. (2003) conducted a study in 
which they surveyed a population of 82 San Francisco based drug users, who reported 
experiencing at least one heroin overdose.  An overwhelming 87% of the participants 
indicated they would be inclined to participate in an overdose training program to learn 
situational awareness and receive take-home naloxone (Seal et al., 2003). 35% of the 
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respondents indicated the distribution of naloxone may allow them to feel more 
comfortable when using heroin and subsequently use higher doses (Seal et al., 2003). 
However, to date, research has not demonstrated that overdose education and naloxone 
distribution programs (OEND) lead to an increase in drug use for participants (Doe-
Simkins et al., 2014).    
Seal et al. (2003) found, if provided naloxone, 62% of respondents reported they 
may refrain from calling law enforcement in the event of an overdose. Notably, 30% of 
participants indicated they would leave the scene following the application of naloxone 
(Seal et al., 2003). Due to the potency of many synthetic opioids currently on the market, 
it is extremely important to monitor an individual following the use of naloxone.  In a 
qualitative study designed to gauge officers’ perceptions on the overdose epidemic, in 
regards to naloxone one officer stated: 
I think it’s a ‘get out of jail free’ card, cause if you take the naloxone, “Oh, you 
know what? Hey, I screwed up and I fell off the wagon. Let me just take  
the naloxone and Ill start over again. It gives them a way out (Green et al., 2013, 
p. 10). 
 
Naloxone and Law Enforcement. As the opioid epidemic continues to worsen and 
overdoes become increasingly prevalent, states have begun to develop new initiatives to 
better combat the growing epidemic. Community-based programs have been key in 
equipping addicts, friends, and family members with opioid overdose training as well as 
an overdose prevention kit, which includes naloxone. Since the late 1960s, paramedics 
have been carrying doses of naloxone to be prepared in the wake of an overdose call. 
However, as opioid overdoses continue to increase, many states along with the Federal 
Government have stressed the importance of equipping other first responders with 
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naloxone (Davis, et al., 2014). Since 2010, the National Drug Control Strategy has urged 
state and local authorities to implement policies, designed to better equip officers and 
first responders with naloxone (Executive Office of the President of the United States, 
2016).  
The Federal Government has also implemented a number of initiatives designed 
to combat the opioid epidemic. The Department of Defense (DOD) has begun to equip 
first responders stationed on military bases with naloxone kits and opioid overdose 
training (Executive Office of the President of the United States, 2016). Since 2013 the 
Department of Veterans Affairs distributed over 45,000 naloxone kits, 39,000 of which 
went to veterans (Executive Office of the President of the United States, 2016).  The 
Food and Drug Administration fast-tracked the evaluation process of Narcan®, the nasal 
spray version of naloxone, in order to provide first responders and laypersons an 
alternative to the injection route (Executive Office of the President of the United States, 
2016). From the fourth quarter of 2013 to the second quarter of 2015, we have seen a 
drastic, 1170% jump in the pharmacy distribution of naloxone (Jones et al., 2016).   
Since the release of naloxone in the 1960s it has been a staple in hospitals, 
paramedic kits, ambulances, and other medical facilities which use prescription opioids. 
As the number of opioid overdoses and subsequent fatalities continues to increase, the 
need for law enforcement, and EMTs to carry naloxone has become a controversial topic. 
The debate is especially pertinent in rural areas, where it may take a longer period of time 
for a paramedic to reach the scene of an overdose. Whereas officers or EMT’s may be 
closer in proximity and able to respond in a shorter period of time. In a study conducted 
in 2006, it was found that by equipping EMT’s with naloxone, the time to reach the scene 
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of the overdose would be reduced anywhere between 5.7 and 10.2 minutes (Belz et al., 
2006). Belz et al., (2006) highlighted the potential efficiency that could be a result of 
utilizing EMTs to respond to overdose calls, rather than paramedics.  
Kitch and Portela (2016) conducted an observational study in which they 
examined officer’s experiences and outcomes when administering naloxone. The results 
indicated that within a 48-hour span, officers who had received training in overdose 
identification and naloxone application, were successful in administering naloxone to 
four overdose victims. Kitch and Portela (2016) explained that although the initial results 
appeared to be positive, equipping law enforcement with naloxone requires funding, 
inner agency communication, and consistent training.   
As the government continues to encourage law enforcement agencies to equip 
officers with naloxone, adversaries cite potential liability charges as a deterrent factor. 
Davis et al. (2015) stated a review of the available research indicated no cases regarding 
law enforcement and naloxone administration.  
Danger for LEO. In 2010, the Office of National Drug Control Policy (ODNP) stated 
“naloxone should be in the patrol cards of every law enforcement professional across the 
nation” (The White House, 2013). With that said, each individual law enforcement 
agency has the autonomy to decide whether or not to equip officers with naloxone. 
Paramedics typically administer naloxone through injection; however, in 2015 the FDA 
approved a nasal spray, commonly referred to as naloxone. Naloxone allows police 
officers to deliver potentially life saving medicine through a nasal spray, subsequently 
avoiding the potential risk associated with needle exposure (Ray et al., 2014). 
Green et al. (2013) conducted a qualitative study in which they examined officer’s 
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attitudes toward overdose prevention strategies. Green et al. (2013) found many officers 
considered it part of their job duties to protect the community and ensure public safety; 
however, a majority of the participants reported concerns regarding the additional 
responsibility of preventing overdoses.  Additionally, many participants communicated 
feelings of helplessness due to the lack of treatment options available for addicts (Green 
et al., 2013). On the topic of law enforcement officers carrying naloxone, one supervisor 
stated “I know I don’t want my officers giving people shots and pills. We get sued for 
enough stuff. Let people with some health training issue that” (Green et al., 2013). 
Gaps in the Research  
Yin (2009) defined a six step process that may be utilized when conducting a 
qualitative case-study. The first step is defined as the “planning stage”. During this time, 
the researcher should conduct a review of the literature and identify any notable gaps. If 
any gaps are identified, the researcher should ensure to utilize research questions which 
may serve to address such topics (Darke, Shanks, & Broadbent, 1998). In this case, the 
researcher examined the opioid epidemic as a whole. The researcher sought to examine 
the ever changing epidemic, the current climate, and the role of law enforcement. By 
examining these topics further, the researcher was able to identify significant gaps in the 
research regarding the ever evolving role of law enforcement officers.  
Although, the current research provides ample detail regarding policy changes 
and applicable statistics which demonstrated how these changes may have affected the 
community, the research fails to examine the thoughts and opinions of the law 
enforcement officers, themselves. As a result of the literature review, I designed a case-
study which will serve to fill the gap in the research. This multiple-case study was 
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designed to provide a better understanding of how six law enforcement officers perceive 
policy changes which require law enforcement officers to carry and administer naloxone. 
Research Questions 
1. How do law enforcement officers, who are mandated by policy to carry and 
administer naloxone, perceive this change in policy? 
2. How do law enforcement officers, who are mandated by policy to carry and 
administer naloxone, describe the potential barriers to the successful 
implementation of naloxone policies?  
3. How do law enforcement officers, who are mandated by policy to carry and 
administer naloxone, view the harm reduction approach of equipping officers with 
naloxone? 
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Chapter 3: Methodology 
Research Method  
Edmonds & Kennedy (2013) stated “the aim of the qualitative method is to reveal 
and understand phenomena within a particular context without attempting to infer any 
type of causation” (p. 112). Often times, qualitative research is used as a means to a pave 
the way for future quantitative analysis, in which causation may be inferred (Edmonds & 
Kennedy, 2013). Due to the lack of available research on law enforcements perceptions 
of using naloxone, this study utilized a qualitative approach in order to develop a better 
understanding of the topic at hand.  
This qualitative study employed the multiple case-study design. Baxter and Jack 
(2008) stated “qualitative case-study methodology provides tools for researchers to study 
complex phenomena within their contexts” (p. 1). When used in the correct context, case 
studies can aid in theory development and program evaluation (Baxter and Jack, 2008). 
Edmonds & Kennedy (2013) argued using a qualitative case-study design prevents the 
researcher from inferring causation or generalizing the results of the study.  
More specifically, by utilizing the multiple-case study approach, I was able to 
examine dissenting and similar views among case participants (Yin, 2003; Baxter and 
Jack, 2008). Yin (2003) stated using a multiple case-study approach allows the researcher 
to identify and develop an understanding of the similarities and differences between each 
case (Gustafsson, 2017). The issue at hand is one of complexity which required an in-
depth study in which multiple perspectives were presented and analyzed.  
A multiple case-study design allowed me the opportunity to explore the views of 
six law enforcement officers. The “case-study” aspect allowed me to develop a deep 
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understanding for each participant’s views. Whereas, the “multiple” aspect allowed me to 
view these perceptions not only individually, but also collectively.  
Participants 
The target population in this study was police officers who are mandated, to carry 
and administer naloxone, if the opportunity presents itself. This study used participants 
from one mid-size, Florida sheriff’s office which enacted legislation which requires 
officers to carry and administer (if necessary) naloxone. Yin (2003) stated “because 
comparisons will be drawn, it is imperative that the cases are chosen carefully so that the 
researcher can predict similar results across cases, or predict contrasting results based on 
a theory” (Baxter and Jack, 2008, p. 5). As stated by Yin, when using the multiple-case 
study approach it is important to hand pick cases (Yin, 2003).  Baskarada (2014) stated 
that the ideal case-study design would include 8-12 participants. However, it is important 
to mention, the number of participants in a case study varies depending on the nature and 
constraints unique to each study.  
Sampling Strategy 
This study is comprised of six, hand-picked officers, from one mid-size, Florida 
sheriff’s office.  Burmeister & Aitken (2012) argued that in order to reach data saturation, 
the researcher must be mindful in determining the sample size. However, it is notable that 
a larger sample size does not automatically ensure data saturation will be reached 
(Burmeister & Aitken, 2012). In actuality the make up of the sample size is instrumental. 
For this reason, it is essential to be mindful and hand select the willing participants in 
order to best fit the study at hand. For this study, the researcher decided to use six 
participants and place more of an emphasis on experience with naloxone based policies, 
   
 
 
 
 
  
 
 
 
70 
 
 
 
 
 
 
rather than expand the number of participants. The participants chosen for the study had 
experience working at the mid-size Florida Sheriffs Office, in the time period following 
the enactment of the naloxone policy.       
This study required the participants to have experience carrying and ideally 
administering naloxone. In order to ensure the participants selected meet the criteria for 
inclusion in the study, purposeful sampling was employed. Purposeful sampling occurs 
when the researcher deliberately selects participants in order “provide information that 
cannot be gotten as well from other choices” (Maxwell, 2005, p. 88).  
Prior to contacting the Sheriff’s Office, I worked through the IRB approval 
process. Once the IRB board granted approval for this study, I identified several Sheriffs 
department located in Florida, which enacted policy that required officers to carry 
naloxone. After researching the departments further, I contacted one mid-size Florida 
Sherriff’s Office to discuss the study further. I was able to pitch the study to the PR 
representative, who then put me in contact with the Undersheriff. The Undersheriff 
agreed to allow LEO’s to participate, if they should choose to do so.  
Through the IRB approval process, I created a recruitment flyer, which provided a 
brief overview of the study as well as my direct contact information. The Undersheriff 
disseminated my recruitment flyer via email to all Law Enforcement Officers employed 
by the selected agency. By providing my contact information, I eliminated the need for a 
middle man, the officers were instructed to contact me directly, if they would like to 
participate, or if they had any questions or concerns.   
The majority of the participants contacted me via email to express their 
willingness to participate. At this point, I utilized the questions in Appendix B, to screen 
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the interested candidates to ensure they meet the criteria for inclusion in the study. I then 
forwarded each candidate a copy of the recruitment flyer to ensure they were aware of the 
purpose of the study, prior to the interview. Some of the participants had further 
questions, which were addressed prior to the interview.  
I then utilized purposeful sampling methods to hand select participants. My goal 
was to employ a diverse sample, in terms of years of experience, in the field of the law 
enforcement. I wanted to ensure the sample covered individuals newer to law 
enforcement, as well as, career officers who may offer a different perspective. 
 As the majority of the officers elected to be interviewed while on shift, there 
were several instances which required us to reschedule the interview. If a participant 
elected to remove himself/herself from the study, I would have employed the snowball 
technique to garner additional participants.    
For the purpose of this study, I chose to interview six participants. The consulted 
research on multiple case-studies varies as to the “right” number of participants. 
However, I believe the number six allowed me to deeply examine the individuality of 
each person, but also allowed me to capture potential themes.  
Prior to the interview, participants were informed that their participation is fully 
voluntary and they may terminate the interview at any time, should they wish to 
discontinue participation in the study. I explained the purpose of the study to each 
participant and presented them with the consent form. I asked each participant to review 
the consent form and we discussed any questions or concerns they may have. I also 
explained, by signing the consent form they are giving me permission to record the 
interview. Each participant was then asked to sign the consent form which indicated they 
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are comfortable with the study, they have been informed of the process, and they are able 
to discontinue participation at anytime. This form is provided in Appendix A.   
Instruments 
It is important for qualitative researchers to be able and willing to evolve a study, 
as the data dictates. Creswell (2013) explained the methodology employed by the 
researcher may be altered or shifted after the researcher begins the data collection 
process. With that said, I found it necessary to approach each participant individually. 
While, I stayed true to the underlying purpose of the research, each interview was guided 
by the participation and passion of each participant.  
Each participant housed different passions and beliefs, if he/she wanted to discuss 
a specific question further, I felt it was important to allow their interests to guide the 
interview. With that said, each interview was guided by a predetermined set of questions 
and the topics discussed remained true to the purpose of this study.     
The data collection method was comprised solely of face to face interviews with 
each participant. First and foremost, the researcher must ensure access to the participants 
(Yin, 2017). Secondly, it is of the utmost importance to ensure the researcher is 
adequately equipped with a laptop, paper and pen for notetaking purposes, and a recorder 
(Yin, 2017).  
It was of the utmost importance to best ensure the comfort of each participant. In 
order to accommodate the participant, I requested each participant to choose the time and 
location of each interview. Yin (2017) stated using a case-study method requires the 
researcher to cater to the schedules and preferences of the participants. Notably, the 
majority of the participants chose to meet during their scheduled work hours. As a result, 
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several interviews were rescheduled due to various work matters.  
Yin (2016) provided several recommendations for a novice researcher to follow 
when conducting interviews. The first recommendation made by Yin (2013) was to 
“speak in modest amounts” (p.144). He further explained it is important to craft the 
interview in a way that will allow the participant to respond in a lengthy manner. As 
many of the participants had a lot to say on the current topic, I was merely there to guide 
the interview. Yin (2017) further explained it is extremely important for the interviewer 
to refrain from asking leading questions to avoid interviewer bias. 
The next recommendation made by Yin (2013) was to be non-directive. He 
further explained “your goal is to let participants express their own meanings as part of 
their own way of describing the world” (p.144). Although I developed an interview 
protocol (Appendix C) which listed pertinent topics and key questions, each interview 
remained fluid in structure. As a result, each interviewee did not receive all of the same 
questions. The interview protocol (Appendix C), was designed to guide the interview and 
ensure I was able to gain insight in to the research questions (Hancock & Algozzine, 
2017).  
Yin (2013) further advised the interviewer to “remain neutral”, “maintain 
rapport”, and “analyze while interviewing”. As the sole researcher and analyzer, it was 
important for me to remain neutral throughout the duration of the study. I did my best to 
harbor any preconceived notions and remain present in each interview. As an employee 
of a law enforcement agency, I was able to gain rapport with each participant through 
common interests and career discussions. This rapport continued throughout the duration 
of the interview, which served to allow for an open discussion.  
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I further utilized a semi-structured approach which allowed autonomy to develop 
and ask probing questions as the interview progressed. Due to the lack of strict protocol, I 
developed a type of social relationship, unique to each each interview/participant (Yin, 
2013; Seidman, 2006). By employing the open-ended interviewing techniques, the 
participants were ultimately free to challenge my line of questioning. With that said, it 
was extremely important to be well-prepared to react in the event the interview went off 
script.  
Procedure/Data Analysis 
One of the biggest hurdles faced in a qualitative case-study is the potential bias of 
the researcher. In this study, I was the primary data collector and therefore the sole data 
collection tool, it is important to address the potential bias that may be present in social 
research. Researchers who are able to identify his/her personal views and distinguish 
personal ideologies will be more successful hearing and digesting the behaviors of others, 
in this case the interviewees (Dibley 2011; Fields & Kafai, 2009).  
The data collection process was managed and enacted solely by me. I am the only 
person responsible for collecting and maintaining data throughout this study. Once I had 
approval from the IRB board and the Sheriff’s department, I contacted each of the six 
participants to schedule an interview. The location and time of the interview was at the 
preference of the participant. I did my best to ensure the interview location was suitable 
for recording purposes. Each interview was conducted in person and utilized and semi-
structured, “shorter” case study interview (Yin, 2017).  
Rubin & Rubin (1995) stated “qualitative interviewing requires intense 
listening…and a systematic effort to really hear and understand what people tell you” 
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(Rubin & Rubin, 1995, p. 17). Due to the importance of understanding, comprehending, 
and analyzing each word and interaction in a qualitative interview, each interview was 
recorded and subsequently transcribed by me.  
Prior to the recording of the interview, I obtained the written permission of the 
interviewee, to ensure the participant was aware and comfortable with the use of a 
recording device (Hancock & Algozzine, 2017). For this study, I utilized a hand-held 
audio recording device. In order to be safe, I utilized two recording devices, to prevent 
reliance on one device. The entire interview from start to finish was recorded. Stuckey 
(2014) explained that by recording the interview, the researcher is free to fully 
concentrate on the conversation and responses of the interviewee, rather than trying to 
write copious notes.  
Additionally, I used a note pad to reflect on notable moments throughout the 
interview. This includes, documenting notable statements, identifying topics which may 
need further questioning, recognizing key points, noting mannerisms or facial expressions 
and any other interactions deemed noteworthy.  
Shortly following the interview, I transcribed the interview in entirety. In this 
case, data transcription aided me in the further analysis and comprehension of the 
interview contents. Transcription is not simply a verbatim rendition of the audio 
recording, rather it is important to recognize the use of tone and inflection to garner a full 
picture of the interviewee (Stuckey 2014).  
Once all of the interviews were completed and the data was transcribed in 
entirety, I began the coding process. Again, this task was completed solely by me, who 
also conducted and transcribed each of the six interviews. This allowed me to draw on 
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memory as well as the data to provide a complete picture of each interview including key 
points and themes.  
Due to the small sample size, I did not utilize a coding software to organize the 
data. In following the interview plan, each participant was asked similar questions, in 
order to promote data saturation.  These questions were grouped by question responses. 
Questions that were not asked to each participant were organized based on similarities. 
Yin (2017) explained that organizing the data in a systematic format will lead to a 
stronger analysis of the data. Once the data was organized and grouped it will serve as the 
data database.   
Yin (2017) stressed the importance of constantly re-reading the data to identify 
the distinctive features and identify key themes and potential new insights. This process 
also helped ensure the data was consistent among all interviews (Yin 2017).  
The use of one researcher minimized the amount of data that needed to be 
modified. Although a coding software was not used, I utilized Microsoft word to formally 
organize electronic copies of the data transcripts and various other documents. 
Additionally, these documents were printed for the coding process.  
Coding 
The coding method allows the researcher to break the data up in to smaller parts 
and then reassemble to tell the narrative (Stuckey 2015). Once the data was coded, I 
examined the data for patterns. During this time, the researcher is constantly questioning 
what statements may mean and how they may be interpreted (Yin, 2017). This aided me 
in determining present themes and interpreting the reassembled data.  
Yin (2017) explained that identifying patterns is the main goal of the assembling 
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phase. There are no constraints in the identification of patterns. These patterns do not 
need to relate to one another, there is no pattern to broad or to narrow (Yin, 2017). 
Essentially, during the reassembling phase, I was familiarizing myself with the intricacies 
of the data. At this stage, I organized the data methodically using arrays.  
As defined by Yin, the next stage in the research process is interpreting the data 
(Yin, 2017). At this point, I developed a strong sense of the themes present in the data. 
During this phase the researcher sought to develop a comprehensive interpretation of the 
data, which included “completeness, fairness, empirical accuracy, value-added, and 
credibility” (Yin, 2017, p. 221). Finally, once the data was interpreted, I drew 
conclusions. Yin (2017) defined several types of concluding actions researchers can take. 
For one, based on the findings, I identified future research needs (Yin, 2017). 
Additionally, I presented the findings and new concepts or theories that were developed 
throughout the course of this research study (Yin, 2017).  
Confidentiality  
 In order to ensure the confidentiality of the participants, I did not include personal 
identifying information. Participants were advised that their participation in this study 
would remain confidential. I stored and will continue to store any documents, forms, or 
collected PII information in a safe location. Any additional confidentiality concerns held 
by the participant were discussed and handled accordingly.  
Limitations 
Yin (2017) stated “a valid study is one that has properly interpreted its data, so the 
conclusions accurately reflect and represent the real world that was studied”. When using 
a case-study research design, the terms internal and external validity are typically 
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replaced by trustworthiness and authenticity (Zucker, 2009). This study relied fully on the 
participation and truthfulness of the participants. In a multiple case-study the researcher 
is dependent on the participants to provide truthful and accurate depictions of their 
thoughts and emotions. However, it is the role of the researcher/interviewer to ensure the 
questions and the atmosphere of the interview cultivated an open and truthful dialogue.  
Although I was unable to control the truthfulness of the participants, I believe 
each interview provided a safe environment for information sharing. Additionally, many 
of the statements made by participants were explained through real life examples or 
situations they had endured.  
 Limitations and delimitations refers to threats to the internal and external validity 
of the study. Specifically, a limitation refers to areas of potential weakness in the study. 
Limitations often result from the design of the study or the employed methodology. On 
the other hand, delimitations are typically a direct result of parameters set or decisions 
made by the researcher. It is important to be cognizant of the potential limitations and 
delimitations.  
 A limitation is a facet of the study or research, which the researcher is unable to 
control but may negatively affect the study or the outcome (Patton, 2003). Unfortunately, 
there are several limitations of the proposed study that should be mentioned. First and 
foremost is the number of participants. This study included six officers; however, the 
years of experience as well as the familiarity with naloxone/naloxone varies among 
participants. Additionally, due to the importance of using individuals who have at least 
baseline experience carrying naloxone, the researcher was unable to randomly select 
participants. However, the goal of this research design was not to generalize the findings 
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of the sample population to all law enforcement officers who are required to 
carry/administer naloxone.  
 Another limitation present in qualitative research is the potential for researcher 
bias. Essentially, the researcher may consciously or unconsciously affect the study with 
the presence of preconceived notions. The researcher’s thoughts and opinions may impact 
the way he/she understands and evaluates the data. This limitation is further exacerbated 
due to the fact that I am the sole researcher, the sole interviewer, analyzer, coder, etc in 
this study.  
 This qualitative study is fully dependent on semi-structured interviews. There are 
several limitations associated with the use of self-report data in a qualitative study. For 
one, you are forced to assume the participants are being forthcoming and honest 
throughout the duration of the interview. This limitation is especially present in the 
current study due to the role of the police chief in implementing the discussed policy. The 
researcher utilized several procedures in order to provide an atmosphere conducive to in-
person interviews: 
1. Participants were fully informed of the general topic of discussion, the initial 
questions which serve to guide the interview, and the interview process. 
2. The comfort of the participant was of the utmost importance, if the participant 
preferred to collect his/her thoughts using written notes, prior to responding to a 
question, he or she was authorized to do so. 
3. Participants were informed that if at anytime during the interview process they 
felt they could not answer a question honestly, the interview would be terminated 
and next step actions will be discussed.  
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4. Interviews were scheduled at the convenience of the participant. I made every 
attempt to ensure the location/time of the interview is convenient for the 
participant.  
The second limitation of this study is the lack of generalizability of the results. This 
study utilized a small sample size, which eliminated the possibility of generalization. In 
addition, the sample was purposefully selected by the researcher in order to ensure each 
participant had applicable experience. As a result, the sample size may not serve to cover 
all demographics. Simon & Goes (2013) stated “case studies may be suggestive of what 
may be found in similar organization, additional research would be needed to verify 
whether the findings from one study would generalize elsewhere.” (p. 2).  
Delimitations 
 Simon & Goes (2013) explained that delimitations arise as a result of the various 
decisions made by the researcher.  Delimitations may include the design of the study, 
choice of variables, interview questions, participants selected, etc. One of the prime 
delimitations of this qualitative multiple case-study is the sample size and the 
participants. In choosing the sample study, the researcher decided to focus on law 
enforcement officers from one agency. As a result, this sample is not representative of all 
law enforcement agents. Secondly, the researcher determined that a sample of six 
participants will be sufficient for the study at hand. However, it is possible that a larger 
sample size would allow the results more generalizability. 
Summary 
The devastation caused by the opioid epidemic has emphasized the desperate need 
for policy, designed to combat the ever-growing epidemic. Often times, desperation leads 
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to policies being implemented as a result of perceived necessity rather than evidence-
based research. Many naloxone advocates, argue there is no harm in equipping law 
enforcement officers. Some may say, “if it saves a life, it is worth it”. However, in 
opposition, one may ask “why equip officers with naloxone to save addicts, when we fail 
to equip officers with epi-pens?”  
Ultimately, the opioid epidemic is not improving and the role of law enforcement 
officers may continue to expand to unprecedented measures. However, to date, the 
research fails to address law enforcements perceptions of this role change. More 
specifically, this study will serve to fill the gap in the research, regarding law 
enforcement officer’s perceptions of carrying and administering naloxone. Although, the 
use of naloxone is relevant and heavily discussed, I believe there is a lack of knowledge 
regarding the perceptions of those affected by these policies, the law enforcement 
officers. The qualitative research design, allowed me to deeply examine the perceptions 
of the six interviewees.  
From the data collected, I was able to garner a better understanding of how this 
policy change affects the day to day operations of the law enforcement officers and how 
they perceive such changes. The results of this study, may aid senior law enforcement 
professionals in better drafting and implementing naloxone policies. 
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CHAPTER IV- RESULTS 
 
Introduction 
This qualitative study was designed to examine police officer’s perceptions of the 
use of NS Naloxone® in the field. In Chapter 4, I will present my findings with a strong 
emphasis on direct quotes made by participants, in order to allow the voice of each 
participant resonate. The data collected in this study was derived from semi-structured 
interviews, with each participant. The findings presented in this chapter are solely based 
on my analysis of the interview transcriptions. In order to ensure each research question 
was addressed, I created an interview guide which split the interview in to three sections. 
Each section was dedicated to a research question. Additionally, I created a series of 
questions for each individual research question. I allowed the interview to progress 
organically and only used the predetermined questions if the conversation required 
guidance. However, the majority of the interviews naturally covered each research 
question and did not require specific probing.   
My knowledge and interest in the topic coupled with the participants’ honesty and 
passion for their job, allowed for a natural and thorough discussion.  The sample size for 
this study, consisted of six individuals employed by a mid-size Florida Sheriffs office. 
All six of the participants were interviewed in person, at a location of their choosing. The 
methodology employed was a multiple-case study design. In order to better examine the 
topic at hand, the following research questions were created: 
RQ1: How do law enforcement officers, who are mandated by policy to carry and 
administer Naloxone, perceive this change in policy? 
RQ2: How do law enforcement officers, who are mandated by policy to carry and 
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administer Naloxone, describe the potential barriers to the successful implementation of 
Naloxone policies?  
RQ3: How do law enforcement officers, who are mandated by policy to carry and 
administer Naloxone, view the harm reduction approach of equipping officers with 
Naloxone? 
Descriptive Information 
The sample in this study was comprised of police officers with experience ranging 
between 2 years and 37 years. These officers were all employed by the Sheriff's Office 
for at least one year and were familiar with the policy regarding Naloxone. The 
participants ranged in age from 27 to 55. All of the participants were Caucasian, there 
was one female and five male participants.  The participants of this study were chosen 
based on their experience level. Purposeful sampling was employed in order to ensure the 
participants had a wide range of experience. 
Data Collection 
The data collection consisted of individual face-to-face interviews with each of 
the participants. All of the participants were employed at the same Sheriff's Department 
located in Florida. Once an officer was selected to participate, he/she was contacted via 
email to schedule a time for the interview. All of the participants were asked to choose a 
location and a time for the interview, in order to facilitate comfort and convenience for 
each participant. The interviews spanned in duration from 30 minutes to 60 minutes.  
Immediately following the interview, the researcher summarized key points, reviewed 
notable statements, and recorded any other pertinent observations. At a later date, the 
interview was transcribed in entirety, by the researcher. The interview was recorded using 
   
 
 
 
 
  
 
 
 
84 
 
 
 
 
 
 
two separate devices, in order to prevent dependence on one device. The devices used 
were an IPhone 7s and the Olympus Voice Recorder. The process remained the same for 
all six interviews. There were no notable mishaps or situations which would have altered 
the data collection process. The collection of the data is further outlined in Chapter 3. 
Interviews 
Each of the six participants were asked to pick a time and location which was 
both comfortable and convenient to him/her. Upon meeting, participants were presented 
with the informed consent form, which educated the participant on the regulations of the 
study and the use of a recording device. At this point, the participants were informed they 
had no obligation to participate in this interview and they may choose to discontinue their 
participation at any time. The participants were also notified that their identity would be 
kept confidential.  Before the interview, I provided a brief overview of my research and 
the purpose of the interview. During the interview, I wrote down key terms and notable 
content, the interview was recorded in entirety and transcribed. Immediately following 
each interview, I wrote down a summary of the meeting, including my reaction, key 
moments, notable body language, etc.   
Theme Development 
One of the rigors of qualitative research is theme development.  The first step in 
theme development is to become well acquainted with the transcripts. In order to do so, I 
first transcribed the interviews in entirety.  Once the interview was transcribed, I listened 
to the recording while reading along to ensure the accuracy of the transcription. While 
reviewing each transcript, I would highlight or notate any memorable statement or 
comment that garnered my attention. Once I developed a deep understanding for each 
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transcript, I reviewed each transcript in conjunction with my interview notes. This 
allowed me to develop a deeper association between the conversational cues and behavior 
I notated and the verbiage provided in the transcript.  
 In order to develop the themes unique to each research question, I broke each 
transcript down to three sections, each section represented one research question. At this 
time, the repetitive nature of qualitative analysis became the forefront. I read section one 
of all six transcripts numerous times in an attempt to identify repetitive words, themes, 
comments, etc. This process was repeated for sections two and three.  Although each 
officer spoke of different experiences and presented individual opinions, there were clear 
and decisive similarities between their experiences and thought process. This allowed for 
the creation of overarching themes, consistent throughout the interview transcriptions. 
These themes are explored at a deeper level, in the section below. The identified themes 
include: duty to serve, protection, life saving measure, frustration, job hazard, temporary 
fix, enabling, little fish-big pond.  
Results 
The current study was intended to develop a better understanding of law 
enforcement officer’s perceptions on carrying NS Naloxone. The interview framework 
was designed to establish a conversational rapport with each participant. The first 
research question asked: how do law enforcement officers, who are mandated by policy 
to carry and administer NS Naloxone, perceive this change in policy? Ultimately, this 
topic of conversation explored the changes in each participant’s job due to the opioid 
epidemic, the use of NS Naloxone in the field, including but not limited to: training, ease 
of use, medical aspects, etc. The interview transcription coupled with conversational 
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cues, and observations made throughout the interview, yielded the following notable 
themes: duty to serve, protection, life saving measures, frustration. Additionally, several 
notable comments/concerns, that did not necessarily belong under a certain theme, were 
explored further below.  
Duty to Serve 
Research question one allowed participants the opportunity to discuss their 
thoughts on carrying NS Naloxone. All six of the participants indicated they agreed with 
the policy which equipped them with NS Naloxone. Notably, each participant was asked 
if he/she would choose to carry NS Naloxone if not mandated by the department, each 
participant answered yes, seemingly without hesitation. The researcher sought to examine 
the question further by asking participants if they felt it would be possible to arrive on 
scene to a drug overdose, without Naloxone, which would render them essentially 
useless. All six participants expressed discomfort at this notion. Three of the officers 
explained it is their duty to serve and Naloxone simply serves as another “tool in their 
tool belt”.  One participant stated, “It’s morally ethically as a human being you see 
somebody who is obviously dying and you feel that you have to do something, you know, 
your still in this business, you choose this career to help people.” 
Additionally, all six of the participants stated they had a duty to serve and protect. 
Three of the six officers, specifically mentioned the impact of the Sheriff in the 
implementation of the policy. Each of these officers portrayed a deep respect for the 
Sheriff and supported his decision. Two of the six officers specifically cited the mission 
statement of their office. One participant stated, “The sheriff’s office mission statement is 
taking care of people, so with that, you know, that is what we are doing, we are savings 
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someone’s life, no ifs ands or buts about it.” 
Protection 
The concept of protection was a constant in the conversation with all six 
participants. Specifically, each participant provided they first started carrying NS 
Naloxone for their own protection. The participants explained that it was a seamless 
transition. Essentially, officers were first equipped with NS Naloxone for their own safety 
and overtime they began to use it on overdose victims. Therefore, it appears none of the 
officers were caught off guard by the policy change. 
 All six of the participants indicated they feel it is necessary to carry it for their 
own protection and the protection of their fellow officers. One participant stated: 
I think it’s a good thing for a couple reasons, one because we are helping to save 
lives, but this Naloxone is also here for our use. Heaven forbid one of us gets 
exposed to something I’ve, heard about in the news, then you know we all carry it 
in our pockets or our vest, and our buddy there can Naloxone us until rescue can 
get there and take care of us. 
 
A second participant stated “Your own partner could easily be just as affected by it and 
you could be saving his life. To me its important not just for the public but also for 
myself.” The six officers I spoke with, overwhelmingly supported carrying NS Naloxone 
for their own protection and the protection of their fellow officers.   
I asked each officer if they could imagine a situation in which they were carrying 
NS Naloxone, but were not authorized to deploy it on an overdose victim. Each 
participant explored the potential legality issues that may arise in such a situation. When 
asked if he/she would feel comfortable carrying NS Naloxone for his/her own protection 
but not using it on an overdose victim, one participant stated:  
I would think that if any law enforcement agency carries it, I think we would be 
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legally obligated. I can’t see any agency where it would be like, its for you guys, 
but not for the people we are serving. 
 
Life-Saving Measure 
The participants were asked if they felt comfortable administering NS Naloxone, 
based on the training, complexity of use, after care, etc. All six of the participants 
explained that the administration of NS Naloxone itself was extremely simple. 
Participants stated that they had to undergo a PowerPoint training which included a short 
video. All of the participants agreed this training was sufficient.  Three participants chose 
to remove the NS Naloxone from their vests to further demonstrate the simplicity of the 
application. Two of the participants admitted the most difficult aspect of NS Naloxone 
was the importance of temperature regulation. NS Naloxone is heat sensitive, therefore 
officers cannot leave Naloxone sitting in their vehicle, they must keep it on their person.  
One participant explained it was no more complex then using Flonase [Flonase is 
an over the counter allergy relief nasal spray]. All six of the participants stated that they 
viewed the administration of Naloxone as a basic lifesaving technique viewed in the same 
light as CPR. When asked if they viewed administering NS Naloxone as a medical 
procedure, one participant stated “No, I wouldn’t say that, because we do CPR, I don’t 
think that’s actually considered a medical procedure, its just some basic life support, 
that’s what I call it, that’s what I would call NS Naloxone, the same thing.” One 
participant referenced the use of tourniquets that would be used for a gun shot wound, 
explaining that Naloxone would be no more medical than applying a tourniquet. Another 
participant stated: 
Have you ever watched someone use Naloxone, you literally just shoot it up the 
nostrils, its not like I feel as if I am not trained enough or I don’t have the skills, 
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there is no skill, you shoot it up their nose, and if necessary give them another 
dose? 
 
All of the participants noted that fire rescue typically arrives within several minutes and 
takes over the scene. Three participants indicated there might be more of a medical 
component in a more rural area, where fire rescue takes longer to arrive on scene.  
Frustration  
One theme constant throughout each interview, was that of frustration amongst 
the participants. Although all six participants explained they are on board with carrying 
and administering NS Naloxone, when the situation arises, four of the six participants 
specifically cited frustration in instances which involved “repeat offenders”. A repeat 
offender refers to an individual who has previously been administered Naloxone by the 
Sheriffs Office/Paramedics. One participant stated “It does become frustrating whenever 
you deal with the same person over and over and over again. I mean I have given 
Naloxone to the same person over three times. Me personally. Two times in one week.”  
The current sheriff’s department assigns officers to specific areas of town, 
therefore, many of these officers have been interacting with individuals in their AOR for 
extended periods of time. One participant explained, he makes an effort to try to get to 
know the people he is interacting with. He further explained it is difficult to watch these 
individuals repeatedly participate in destructive behavior.  
The second research question asked: how do law enforcement officers, who are 
mandated by policy to carry and administer Naloxone, describe the potential barriers to 
the successful implementation of Naloxone policies? This research question was designed 
to develop a better understanding of the potential complications that may arise when 
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deploying NS Naloxone. The interview transcription coupled with conversational cues, 
and observations made throughout the interview, yielded the following notable themes: 
job hazard. 
Job Hazard 
Each participant was specifically asked if he/she was concerned of the 
media/societal backlash in the event that something went wrong while administering 
Naloxone. Three of the six participants stated that regardless of the outcome in any given 
situation there will be media backlash. One participant stated “were viewed in a negative 
light anyway. Regardless... We could save someone’s life, and we do, and the media and 
a small percentage of society, it doesn’t matter what we do, were wrong.” Another 
participant stated “From my experience, doing this for a little bit, it doesn’t matter what 
you do, if something goes wrong, its going to be all your fault, at least according to the 
media and certain portions of society.” A third participant stated that “I’d like to think 
that they would look at it like deputies did everything within their knowledge and 
ability...there is always a few people who will say what they want to say, it is, what it is.” 
These three participants explained that the job hazards associated with Naloxone are no 
different than a simple traffic stop. In either situation if something goes wrong, the 
situation will be constantly analyzed in the media.  
Two other participants stated there were no concerns with administering 
Naloxone. One stated “One of the beauties of Naloxone, is that if you use it on a person 
that doesn’t need it, there is no negative effects, no side effects.” He went on to further 
explain that if something were to go wrong, “there is a law that covers us, if we are acting 
in good faith and we have proper training so that if we do something and it goes wrong, 
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especially on the medical side.” Ultimately these five officers were aware that every 
action they take as a LEO will be scrutinized; however, they were no more concerned 
with this scrutiny when it comes to Naloxone than any other situation they would 
encounter on the job.  
The one dissenting officer cited a concern, not with the media or the perception of 
the situation, but with his safety and the safety of his fellow officers. This officer was in 
his twenties and no more than 150 pounds. He explained that oftentimes upon revival, 
individuals wake up disoriented, sick, combative, confused, etc. In fact, he made it clear 
that you really have no idea what to expect when an individual is “coming to” after being 
administered Naloxone. The participant noted oftentimes you are administering Naloxone 
in a room full of needles, unaware of the surrounding environment, and may be dealing 
with a subject large in stature. He explained the importance of surveying the surrounding 
environment and ensuring he is a position to best ensure his safety and the safety of the 
other individuals at the scene.  
The third research question asked: how do law enforcement officers, who are 
mandated by policy to carry and administer Naloxone, view the harm reduction approach 
of equipping officers with Naloxone? This research question was designed to develop a 
better understanding of officer’s views on harm reduction policies in the context of law 
enforcement strategies. The interview transcription coupled with conversational cues, and 
observations made throughout the interview, yielded the following notable themes: 
temporary fix v. permanent solution, enabling, and little fish/big pond. 
Temporary Fix 
 All six of the officer’s interviews considered Naloxone a temporary fix to the 
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opioid epidemic. Five of the six officers did not support the use of harm reduction 
policies. One participant stated “That’s not our place, we are a law enforcement agency, 
the only reason the Naloxone is even on our radar, is the lifesaving aspect.” A second 
officer did not support the use of harm reduction policies and cited a personal reason. He 
stated:  
I live in this community; I raise a kid in this community. So, someone using 
heroin and then getting Naloxone doesn’t solve the problem. I don’t want my kid 
around someone using heroin, I want that person to go to jail. 
 
A third participant stated “I just don’t like the fact that the government, my tax dollars are 
paying for it.” This participant further explained that his/her mother had passed away 
from an illness, one of which she did not choose to have, and the government failed to 
“pitch in” for her treatment costs. The one dissenting participant stated: 
I think the harm reduction at this point, especially at this point in my career, is a 
good thing, I mean we want to put something with that, you know try to get them 
away from the drugs with something, counseling, whatever they can do, it has to 
be more than just that, it has to be a combination, or everything. 
 
This participant explained that he would expect newer officers to have a stronger stance 
against harm reduction. However, he explained that with experience he started to see the 
potential benefits of a harm reduction approach.  
Enabling 
Three of the six participants indicated that carrying NS Naloxone was enabling 
drug users. One participant stated that indeed it was enabling; however, it was better than 
the alternative option. Another participant stated administering Naloxone with no legal or 
financial repercussions is enabling. All three participants cited the cost of NS Naloxone 
and the lack of responsibility of the individual once the NS Naloxone has been deployed. 
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Participants were frustrated that individuals were given Naloxone and then let go with no 
further action.  
The remaining three participants did not view Naloxone as enabling. Two of these 
participants cited not all overdoses are a result of an addict injecting heroin. One 
participant stated that Naloxone is a preventive measure: 
It is no different then getting any other medical equipment yourself, you can go 
online and get medical equipment to address a gunshot wound and I don’t think 
people are going out planning on getting shot, or planning on overdosing. 
 
He explained that it is not enabling because addicts are not planning to overdose just 
because they know Naloxone may be available.  
Another officer stated the use of Naloxone was a reactive measure, rather than a 
proactive measure. He further described that he does not support harm reduction because 
it is proactive in nature; whereas he supports administering Naloxone because it is a 
reaction to a situation rather than actively cultivating the situation.  
Little Fish Big Pond 
In order to fully address research question number 3, officers were provided the 
below information regarding the 911 Good Samaritan Act in Florida.  
893.21 Drug-related overdoses; medical assistance; immunity from prosecution. — 
“A person acting in good faith who seeks medical assistance for an individual 
experiencing a drug-related overdose may not be charged, prosecuted, or penalized 
pursuant to this chapter for possession of a controlled substance if the evidence for 
possession of a controlled substance was obtained as a result of the person’s seeking 
medical assistance. 
(2) A person who experiences a drug-related overdose and is in need of medical 
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assistance may not be charged, prosecuted, or penalized pursuant to this chapter for 
possession of a controlled substance if the evidence for possession of a controlled 
substance was obtained as a result of the overdose and the need for medical 
assistance. 
(3) Protection in this section from prosecution for possession offenses under this 
chapter may not be grounds for suppression of evidence in other criminal 
prosecutions” (Florida Statue 893.21)” 
Essentially, this Act prevents law enforcement officers from charging or arresting 
individuals based on information that is identified through a call for medical assistance. 
Two of the participants indicated they felt this law impeded their ability to do their job. 
One of which stated “I think it hinders us a little bit you know, but at the same time, if it 
saves a life, it saves a life. Hopefully the person turns themselves around from it.” 
All of the participants recognized the act was necessary to encourage bystanders 
to call law enforcement and potentially save a life. One officer stated “No, because part 
of our job, is not just to put people in jail, its to help them.” A second officer explained 
that often times the individuals who are overdosing are “the little fish in the big pond.”  
He further elaborated: 
But the issue with a lot of the street level users, you know their addicts, as soon 
as they get 20 dollars in their pocket, there going and spending it on their dope 
and there only buying enough to use it right then and there, there not buying a 
week worth. A lot of times, I’ve seen people overdose while their driving on the 
way home from buying their dope. They haven’t made it a half mile down the 
street before they start shooting up their doing it at red lights and stuff like that 
and what they bought is gone. So, you’ll find a needle, an empty bag with some 
residue in and a spoon, that’s it. They don’t have kilos of heroin or something, but 
you know I mean a lot of the people that we search who are users, there carrying 
empty bags.  That’s all they have left on them, a needle and an empty bag. 
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Another officer explained that even if an overdose happened to occur at a prominent drug 
house, “usually our drug dealers will drag them outside and drop them in the driveway, 
so we don’t go in the house.” The same officer provided that many of the people he has 
come in to contact with are unaware of this act. He explained that often times he needs to 
inform the victim that he/she cannot be criminally charged based on any information 
gathered at the scene. Ideally, this would allow the victim to speak more openly with the 
officer. However, the officers unanimously held that the majority of the victims are 
unwilling to provide any information that would give away their drug source.   
Notable Findings 
One overarching theme that was consistent throughout the duration of the 
interviews was that of accountability and financial burden. Regardless, of the officer’s 
personal point of views on the use of Naloxone, their interpretation of addicts, or the 
epidemic as a whole, each officer mentioned the financial aspect of Naloxone, numerous 
times throughout the interview. The consulted information yielded a dose of NS 
Naloxone costs about $50.00.  The participating organization dedicates a portion of their 
budget to fund the use of Naloxone by the department. The literature suggests that other 
agencies may finance the use of Naloxone through different measures including but not 
limited to: grants, donations, federal funds, etc.  
One participant likened it to the use of CPR or an AED. He first stated that an 
individual who has a heart attack and goes unconscious is not being charged for CPR or 
the use of an AED. He then stated “people could have the argument, you can’t help if you 
have a heart attack or a drowning victim, people choose to inject those drugs.” Another 
officer stated: 
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The cost of it bothers me, you know its like 48 dollars a dose, but then you look at 
it like what’s the cost of a life. I don’t know I just have a real hard time with the 
whole, thing, that’s a choice your choosing drugs, and society has to pay the price.  
 
A third participant stated: 
It is 50 dollars a pop. 50 dollars per dose, so somebody may require 3 or 4 doses, 
there’s 200 bucks. Are you taking Naloxone and using it on somebody who 
obviously doesn’t care and now we don’t have resources for somebody else? 
 
Ultimately, regardless of the financial aspect, all of the officers interviewed did not see a 
way around the use of Naloxone by law enforcement. 
Throughout the interviews, there were several notable comments that deserve 
further attention. First and foremost, two participants specifically mentioned the life-
saving award, or more specifically, lack thereof.  The participating agency typically 
presents life saving awards to officers who are credited with saving a life. A typical life 
saving award may be given for administering CPR, saving a drowning victim, using 
AED, etc. There is no argument that administering Naloxone would in fact be considered 
a life saving action. However, the participating agency does not present officers with a 
life saving award for Naloxone saves.  
One participant stated “I pull a little kid from a pool, or pull someone from an 
ocean, those are life saving awards, Naloxone? You deploy Naloxone and save 
someone’s life, it doesn’t count?” When asked why this is the case the participant 
responded “Because there’s so many of them, there’s so many of them, initially there 
were, but they didn’t realize how many.” A second participant stated the previous year 
there were at least 150 Naloxone saves in the department, alone. He went on to explain 
that when officers were first equipped with Naloxone, a Naloxone save would have 
yielded a life saving award. He then stated the policy was changed because “150 life 
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saving awards in a year that would be ridiculous.”  
 The second notable comment made by several officers was the fact that there are 
other portions of their job as a law enforcement officer that they may not agree with. 
However, their job is not to enact policy changes or judge an individual based on their 
actions. Their job is simply to “serve and protect”.  One participant stated: 
I may not agree with, there’s a lot of things I don’t agree with, when I go to the 
domestics and I respond to the same house, for the fourth time, and we have 
provided you with all these resources, and you say your going, your tired of him 
beating on you, and we go back the fifth time, and now your almost lifeless, 
because he beats you to a pulp. That’s not my choice, I just provide the 
consequences, its your life. And you’re the one that has to live that life, with the 
consequences one way or the other, I may not agree with it, but I don’t live the 
jerry springer lifestyle and I’m ok with that. I tell people that, you can live 
whatever lifestyle you want and it doesn’t affect me, ya I am paid to be here, but I 
also love my job, you know, so, and things have changed so much in the 25 years 
since I’ve been here. 
 
Another participant stated “there’s a lot of things in our job that we do that I personally 
feel that we shouldn’t do, because people kind of see law enforcement as an overall end 
all be all.”  
Ultimately, today the discussion is Naloxone, but tomorrow it may be something 
else entirely, the officers interviewed were willing to do what needs to be done, at the 
discretion of their Sheriff, to successfully do their job, regardless of their personal 
opinions. 
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CHAPTER V: Discussion, Conclusions, Recommendations 
Introduction 
This qualitative multiple case-study was designed to examine police officer’s 
perceptions of carrying and administering Naloxone in the line of duty. Ideally, I hoped 
to provide the officers the opportunity to share their side of the story. The good, the bad, 
and the ugly, of policing in regards to the opioid epidemic. This chapter includes a 
discussion of major findings. 
Interpretation of the Findings  
While each officer’s personal experience, perceptions, and professional careers 
differ greatly, each of the eight identified themes were applicable to the perceptions of 
each officers. The identified themes go far beyond the use of Naloxone, rather, they 
encompass the officer’s dedication to their job and preserving the safety of their zip code.  
Duty to Serve 
This study concluded that the officers interviewed simply believe they have a duty 
to serve. When asked their thoughts on using Naloxone in the field, every participant 
answered that it was their job to serve the public and ensure safety. Today, that includes 
carrying and administering Naloxone; tomorrow, it could be something entirely different, 
either way they will serve and protect.  
The available research consulted for this study yielded similar findings. Purviance 
et al. (2017) conducted a study in which they examined law enforcement attitudes 
towards Naloxone training. The results yielded that law enforcement personnel are 
“receptive to Naloxone policies and that officers can be effectively trained to recognize 
and intervene in an overdose” (Purviance et al., 2017, p. 3).  
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Smyser & Lubin (2017) conducted a survey of police chiefs in Pennsylvania, 
“60% responded they strongly agree or agree, the benefits of Naloxone programs 
outweigh the risks.” Ultimately, the data collected indicated various opinions on drug 
users, legal policy, treatment options, etc.; however, the participants were unanimous as 
to the benefits of carrying Naloxone and the opportunity to save a life. 
Protection  
 As I was conducting the research for this study and creating the interview guide, I 
was completely naïve to the fact that many officers were carrying Naloxone for their own 
protection, far before they were mandated to carry it for use on the public. This 
realization was two-fold, for one, because officers were already equipped with Naloxone 
the transition from personal use to public use was relatively seamless. When asked if they 
would choose to carry Naloxone, even if it wasn’t mandated, the response was a 
unanimous “yes”. All of the participants stated he/she felt more comfortable knowing it 
was available in the event himself/herself or a partner or dog was exposed to an unknown 
substance.  
 In the recent years, there have been numerous articles, news broadcasts, first hand 
accounts, etc. of officers or animals in the line of duty being exposed to opioid’s. Opioids 
such as fentanyl and Carfentanil are extremely high in potency and even minute 
quantities can be life threatening to those exposed. A police officer in Ohio, Chris Green, 
had a near death experience, when he patted down a suspect and subsequently got white 
powder, possibly fentanyl on his hands (CBS News, 2017). It took four doses of 
Naloxone to revive Officer Green after the exposure. Brian Foley a deputy chief in 
Hartford recalled a situation in which exposure to fentanyl and heroin, sent 11 SWAT 
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members to the hospital (CBS News, 2017).  
Not only are officers in danger of opioid exposure, but the K-9s, who frequently 
accompany officers on drug busts or raids, can absorb opioids through their paws which 
makes a drug bust extremely dangerous for these animals. In a 2016 DEA paper, officials 
provided “Canine units are particularly at risk of immediate death from inhaling fentanyl” 
(Cima, 2018). Deputy Chief Foley explained officers initially wanted to carry Naloxone 
to ensure the safety of the K-9’s (CBS News, 2017). Andy Weiman, a detective and dog 
trainer, explained the dogs can overdose on such a minute quantity, nothing more than 
two or three granules of sand (CBS News, 2017).  A sergeant located in Greenville South 
Carolina stated “"It gives us a safety net," he said. "Our big thing is an ounce of 
prevention - preventing an incident for the civilians, the officers or the K-9s” (CBS 
News, 2017, p.1).  
Life Saving Measure 
 The AED, perhaps one of the most commonly used life-saving measures is known 
for its ease of use and application. Not only is the AED extremely straightforward, but it 
will also provide verbal commands to streamline the process. A majority of the 
participants interviewed emphasized the simplicity of Naloxone, explaining it rivals the 
AED for ease of application. One participant likened the application of Naloxone to that 
of Flonase (nasal spray used for allergies). The participants interviewed felt Naloxone 
was a life-saving measure, no different than CPR, and AED, or any other basic life-
saving measure they would deploy. To put it simply, another tool in their tool belt.  
 The literature to date echoes these sentiments. A deputy chief in an Illinois police 
department, Tom Keane, offered that Naloxone will join AED’s and most likely become 
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an integral component of police first-aid kits (Wethal, 2015). Keane further stated “The 
technical operation part of it, you could open it up and use it without any training. This is 
just so easy” (Wethal, 2015). Kenyon (2018) explained the training for law enforcement 
on Naloxone “goes hand in hand with CPR training, the idea being that law enforcement 
may be able to take life-saving action before medical aid arrives” (p.1). Interestingly 
enough, several of the interview participants mentioned the Naloxone training would be 
combined with the CPR training for an annual refresher.  
Ray et al. (2015) conducted a study designed to gauge LEO’s attitudes towards 
intranasal Naloxone training. The results indicated that “Naloxone training was not 
difficult and that trained officers felt it would be relatively simple to use Naloxone at the 
scene (Ray et al., 2015, p. 110).  
Frustration 
 At some point during each interview, every officer displayed some measure of 
frustration at the current state of affairs, in regards to the opioid epidemic. The frustration 
stemmed from a variety of different issues including: the lack of accountability from drug 
users, the lack of available treatment resources in the community, the price of Naloxone, 
the cycle of addiction, and most of all their inability to make a dent in tackling this 
epidemic.  
 The available research emphasized many of these frustrations. Notably, the 
research available which pertains to law enforcements views on carrying Naloxone is 
lacking. However, there have been studies which present point of views, other than 
LEO’s, which offer similar findings as this study. Haug et al. (2016) found nurses, EMTs, 
and other health care providers, experienced the highest levels of “burn-out, fatigue, and 
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stigma regarding Naloxone and overdose.”  
For the purpose this study, law enforcement, as a Naloxone carrying agency, 
would be considered a health car provider. A recent study conducted in Baltimore, found 
Baltimore emergency service medical providers often portrayed pessimistic attitudes 
toward programs designed to reduce overdose, such as Naloxone (Haug et al., 2016). 
Job Hazard 
 Each participant was asked if carrying and administering Naloxone presented a 
new set of concerns, in terms of legal liability. In response to this question the majority of 
the participants gave me a blank stare. Overall, the participants responded, every action 
they take is scrutinized, whether they are in the right, the wrong, or the unknown.  
Essentially, when they put on the uninform, they are open to the hazards of the 
job, which unfortunately includes public scrutiny. It appears that the majority of the 
participants viewed Naloxone in the same light as a routine traffic stop. Could things go 
wrong? Sure. Could they save a life? Sure. Could the situation be interpreted incorrectly? 
Absolutely.   
Davis et al. (2015) explained some departments have held off on equipping 
LEO’s with Naloxone, citing agency and officer liability concerns. However, Davis et al. 
(2015) concluded “liability risks related to Naloxone administration to reverse suspected 
opioid overdose are similar to or lower than those of other activities in which LEOs 
commonly engage” (p. 1531). With that said, the participants were overwhelmingly 
satisfied with the training they received regarding using and handling Naloxone. None of 
the participants felt unprepared or hesitant to deploy Naloxone, in a permitting situation.  
 This study is consistent with pervious research which concluded police officers 
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were well trained in administering Naloxone. Fisher et al. (2016) found police officers 
who underwent Naloxone training were able to accurately identify symptoms associated 
with an opioid overdose. The same study found officers were able to deploy Naloxone on 
an individual without “significant adverse effects or outcomes” (Fisher et al., 2016, p.1). 
Fisher et al. (2016) concluded the use of Naloxone by police “does not result in a 
significant incidence of combativeness or need for scene escalations such as immediate 
detention” (Fisher et al., 2016, p.1). 
 Ray et al. (2015) conducted a study in which they surveyed 117 police officers. 
The results indicated the majority of officers surveyed “would not fear aggression or 
withdrawal systems as a result of Naloxone, nor worry they concerned about injuring the 
overdosing victim or doing something wrong during the overdose” (Ray et al., 2015, p. 
5).  
It is important to note, one participant of the current study cited the importance of 
surveying the situation to ensure he/she is aware of size and potential strength of the 
victim. He/she has been in numerous situations where the patient has woken up agitated 
and discombobulated. You can never be sure how the patient will react once revived; 
therefore, officers must be cognizant of the surroundings to ensure safety. This sentiment 
has been echoed by several police chiefs, who refuse to equip officers with Naloxone due 
to the potential dangers.  
Temporary Fix 
 In today’s day and age, we have seen a shift from “tough on crime” policies to an 
approach more parallel with the theory of harm reduction. This study aimed to develop a 
better understanding for the participant’s views on their evolving role in a harm reduction 
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approach. The current study added to the body of research, in which law enforcement 
officers, view Naloxone as a temporary fix to a growing issue. The majority of the 
participants expressed a sense of futility on the topic. Explaining that once the Naloxone 
has been deployed, an individual is relatively free to go on about his/her life with no 
repercussions or treatment options. Furthermore, if an individual does express interest in 
checking in to a treatment center, there is no guarantee of funding, space, etc. Oftentimes, 
by the time a treatment center has availability, an individual is no longer amenable to the 
idea. 
 This sense of futility by law enforcement is consistent with previous research. 
Although law enforcement and other health care professionals consider Naloxone an 
effective life-saving tool, they recognize that it does not address the underlying causes of 
the addiction (Kenyon, 2018). Hence, the high number of individuals who overdose more 
than once. Green et al. (2013) concluded, law enforcement officers felt a sense of 
helplessness, in regards to the opioid epidemic, due to the lack of treatment options 
available. This sentiment was echoed by upper management of one law enforcement 
agency, who recognized the frustration of the LEO’s and the lack of available resources 
for those in need (Green et al., 2013).  
Enabling  
 Discussing the concept of enabling in a harm reduction context is a catch-22. 
Whereas individuals who are opposed to the harm reduction tactic would most likely 
argue that harm reduction as a whole, could be viewed as enabling. Proponents of harm 
reduction, don’t view it as enabling, rather, reducing harm. The current study was 
consistent with previous research, which demonstrated conflicting views among 
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participants. Notably, regardless of the response, in the current study, each participant 
was unable to answer the question without a pause and a thought. Several participants 
smirked and proceeded to ponder before responding. Ultimately, three participants 
eventually concluded that they do consider the widespread availability and ease of access 
to Naloxone, enabling.  
Haug et al. (2016) explained that individuals who oppose Naloxone are fearful the 
accessibility and widespread use of Naloxone will provide a false sense of security for 
users and in turn increase opioid related overdoses and dissuade users from seeking 
treatment.   
Banta-Green et al. (2013) surveyed police officers and paramedics to determine 
their knowledge of Naloxone and immunity laws in Seattle, Washington. One law 
enforcement officer stated: “I would not want Naloxone to be a safety net allowing 
greater use of drug” (Banta-Green et al., 2013, p. 1105). Additionally, several law 
enforcement officers wrote comments which indicated the belief that “Naloxone enables 
drug use” (Banta-Green et al., 2013, p.1105).  
Green et al. (2013) found the law enforcement officers consulted were concerned 
about the type of message conveyed by allowing the widespread use and administration 
of Naloxone (Beletsky et al., 2009; Burris et al., 2009). In the study conducted by Green 
et al (2013), one participant stated “I think it's a ‘get out of jail free’ card, cause if you 
take the Naloxone, “Oh, you know what? Hey, I screwed up and I fell off the wagon. Let 
me just take the Naloxone and I'll start over again. It gives them a way out” (p. 680). 
Little Fish - Big Pond 
 The current study indicated that law enforcement professionals do not believe the 
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“Good Samaritan Law” impacts their ability to do their job. Although, several 
participants did acknowledge situations which may have garnered frustration, they further 
explained the “Good Samaritan Law” does more good than harm. Additionally, the 
participants of the current study explained that they use the overdose calls as an 
information gathering mechanism.  
Occasionally, concerned family members and friends are willing to provide the 
LEO’s with specific information pertaining to the drug source, etc. The participant further 
explained the typical overdose call is for a street level user; this type of user typically 
doesn’t have copious quantities of illicit substances; therefore, the “Good Samaritan 
Law”, is typically not saving drug dealers from prosecution.   
This finding is consistent with the literature, which indicates the “Good Samaritan 
Law”, which encourages by-standers to report an overdose and potentially save a life, is 
worth the inability to prosecute based on the information found on the scene. Banta-
Green et al. (2014) found that some law enforcement officers were not set on enforcing 
drug laws at the scene of an overdose, prior to the enactment of the Good Samaritan 
legislation.  One participant stated “I feel people should respect the law, but people’s 
lives are more important. I wasn’t enforcing drug laws at OD’s before the law” (Banta-
Green et al., 2014, p. 1196). Another participant argued that a simple drug possession 
charge, wasn’t worth an individuals’ life (Banta-Green et al., 2014).  
The BJANTTAC (n.d.) reported, overdose reversal programs, implemented by 
Law enforcement agencies, were found to strengthen community ties and in turn improve 
the ability to gather intelligence. A police lieutenant located in Quincy, Massachusetts 
postulated “Good Samaritan” immunity, not only encourages bystanders to seek help in 
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the wake of an overdose, but also strengthens ties between police and the public (Davis et 
al., 2014). 
Harm Reduction Theory  
 Costigan et al., (2003) defined harm reduction as “the prevention of adverse 
consequences of illicit drug use, without necessarily reducing their consumption” (p. 35). 
This study sought to examine law enforcement officer’s perceptions of harm reduction 
tactics in a law enforcement element. The results of the study were notable; yet, 
conflicting. Five of the six participants indicated they did not see a place for harm 
reduction tactics in law enforcement elements. However, all six participants were on 
board with the use of Naloxone by law enforcement officers.  
Each participant was asked if he/she viewed equipping LEO’s with Naloxone as a 
component of harm reduction, all six officers answered yes. One participant explained 
there was a difference between a reactive and a proactive response. Deploying Naloxone 
at the scene of an overdose is a reactive life saving measure. Other harm reduction tactics 
such as needle exchange programs, safe injection sites, etc., are proactive measures, 
which seemingly encourage drug use.  
Assessing Trustworthiness 
It is no secret that qualitative and quantitative researchers often clash when 
discussing the quality of qualitative research. One of the disagreements is centered 
around the evaluation criteria for qualitative research. Ultimately, the disunion led to 
innovation in the evaluation of qualitative research (Smith et al., 2009).  Qualitative 
research is now often evaluated by assessing the trustworthiness and credibility of the 
study, rather than the validity and reliability.  
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In order to build trustworthiness in the study, I followed the steps as 
recommended by Yin (2017) in the book entitled “Qualitative Research from Start to 
Finish”.  As explained by Yin (2017), “the goal is to instill trustworthiness in the methods 
used to generate the data rather than to debate over the inherent “truthfulness” of the 
data” (Yin 2017; Gibson & Brown, 2009). First and foremost, Yin (2009) held, your 
study provides specifics as to the selection of your topic, study site, participants, and data 
collection methods. In chapter three of this paper, I provide this information in great 
detail.  
Secondly, Yin (2017) offered the importance of demonstrating authenticity of 
your study. Authenticity is derived from the soundness of data, essentially referring to the 
accuracy of the information provided by the participants. (Yin, 2017). This study is 
wholly dependent on the participation and honesty of the participants. This is mentioned 
in further detail when discussing the limitations. With that said, each participant 
volunteered to participate on their own accord and they were given the opportunity to 
discontinue the interview at any time. Additionally, the majority of the conversation was 
derived from real life examples they provided, which may have shaped their 
opinions/experiences. Although authenticity cannot be guaranteed, the participants were 
real and raw in their responses, which led to rich and fruitful data.  
 Baxter and Jack (2009) provided several principles of qualitative research that can 
be followed in order to improve the quality of the study and ensure trustworthiness. One 
of which is to clearly define the case-study research question and ensure the research 
question is substantiated in the findings (Baxter and Jack, 2009). This was accomplished 
by consulting the original research question throughout all steps in the research process. 
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This allowed me to ensure I was staying on track with the original research question and 
as a result, the data collected would speak to the topic of study. I created an interview 
guide filled with questions, designed to address each research question. These questions 
allowed me to guide each interview, while still allowing the conversation to flow. 
Additionally, before each interview, I explained the purpose of the interview; This 
ensured the participants and I were on the same page, as to the topic of conversation.  
Other suggestions offered by Baxter and Jack (2009) include member checking 
and reflection notes. Member checking was often employed throughout the interview in 
order to ensure I was correctly interpreting a participant’s mannerisms, expressions, and 
words. For example, if a participant provided a convoluted response to a question, I 
would often repeat the key points back to he/she to ensure that I was comprehending the 
purpose of the statement. This allowed the participant to correct me, if I interpreted the 
comment incorrectly.  
 Reflection notes were taken throughout each interview. Although, interviews 
were recorded and transcribed in full, it was important for me to take notes throughout 
the interview to record key words and notable statements, but also to keep note of facial 
expressions, notable pauses, and other conversational cues, that are not available through 
a transcript. These notes were consulted throughout the transcription and coding process. 
Limitations  
A limitation is a facet of the study or research, which the researcher is unable to 
control but may negatively affect the study or the outcome (Patton, 2003). There are 
several limitations of the current study that should be mentioned.  First and foremost is 
the number of participants. The study included six officers; however, the years of 
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experience as well as the familiarity with Naloxone will vary among participants. 
Additionally, due to the importance of using individuals who have at least baseline 
experience carrying/administering Naloxone the researcher was unable to randomly 
select participants.  
In order to ensure the level of experience was ranged throughout the participants, 
this study utilized purposive sampling. Although purposive sampling was utilized and the 
participants in turn had a wide range of experience, the small sample of willing 
participants prevented the researcher from better addressing diversity in the sample size. 
For example, the sample consisted of one female and five males, all of Caucasian 
descent. Therefore, a limitation of the study is the lack of diversity in the sample.   
Next, as with all qualitative studies, the data collection process was fully 
dependent on the truthfulness and the willingness to share personal opinions and beliefs, 
by each participant. I addressed this limitation by allowing all participants the 
opportunity to discontinue the interview, if at any point he/she felt uncomfortable. I hope 
that by giving participants this opportunity throughout the interview, they would all 
choose to discontinue rather than share falsified information. Secondly, I made every 
attempt to establish conversational rapport with each participant to cultivate an 
environment suitable for information sharing and gathering.  
 Another limitation of the current study is the potential for researcher bias. As the 
sole researcher, data collector, and analyzer in the study, it is possible I developed 
preconceived notions prior the data collection phase.  As I was aware of this potential 
issue, I made every effort to review the data with an open mind, free from pre-conceived 
notions. I found that transcribing the interviews as well as documenting notes of 
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reflection, aided in my ability to remain neutral.  
The final limitation of this study is the lack of generalizability of the results. This 
study utilized a small sample size, which eliminated the possibility of generalization. In 
addition, the sample was purposefully selected by the researcher. As a result, the sample 
size was not diverse in demographical terms. Simon & Goes (2013) stated “case studies 
may be suggestive of what may be found in similar organization, additional research 
would be needed to verify whether the findings from one study would generalize 
elsewhere.” (p. 2). Although this limitation could not be fully addressed through my 
actions, this study addressed a topic that was lacking necessary research and identified 
numerous avenues for future research.   
Delimitations 
 Simon & Goes (2013) explained that delimitations arise as a result of the various 
decisions made by the researcher.  Delimitations may include the design of the study, 
choice of variables, interview questions, participants selected, etc. One of the prime 
delimitations of this qualitative multiple case-study is the sample size and the 
participants. In choosing the sample study, the researcher decided to focus on law 
enforcement officers from one agency. As a result, this sample is not representative of all 
law enforcement agents. Secondly, the researcher determined that a sample of six 
participants will be sufficient for the study at hand. However, it is possible that a larger 
sample size would allow the results more generalizability. 
Suggestions for Future Research 
First and foremost, the results of the current study only focused on law 
enforcement officers from one Florida Sheriffs office. Although the current department 
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has rural areas, it is important to conduct a similar study in a primarily rural area. Due to 
the quick response time of first responders in more urban areas, deploying Naloxone may 
further affect a department located in a rural area rather than an urban area.  
Secondly, the current research identified a sense of desperation among law 
enforcement officers at the current state of the opioid epidemic. Future research is needed 
to determine how to better address drug laws and how they may impact the opioid 
epidemic.  
Finally, harm reduction tactics are relatively new, when discussed in conjunction 
with the opioid epidemic. As a result, I believe there is often a negative connotation 
associated with utilizing such measures, especially in conjunction with law enforcement 
efforts. This area is a bit of an unknown and applicable research could serve to educate 
policy makers, the public, law enforcement, etc. Perhaps, if people were aware of the 
potential benefits of such programs they would be more willing to participate.  
Implications of Study 
 The current study study focused on police officers use of NS Naloxone in the 
field. It also examined these officer’s views towards harm reduction tactics in 
conjunction with law enforcement elements. Ultimately, the study indicated that although 
the officers appeared to dislike the idea of harm reduction tactics, they were fully on 
board with carrying and administering Naloxone. Ultimately, this study might prove 
applicable for instances other than the use of Naloxone. It is possible, that law 
enforcement officers would approach any situation as they have the current; do what is 
necessary to save lives, protect the public and ensure the safety of fellow officers.  
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Reflections 
This process was eye opening and rewarding. Each interview was unique, yet 
strikingly similar. However, the lessons I learned from each discussion were vastly 
different. First and foremost, the rumors you hear are true, the opioid epidemic affects 
individuals from all wakes of life. Law enforcement, first responders, health 
professionals, friends, families, etc., although the experiences may differ, the devastation 
is the same. Several months ago, I came across an article which highlighted a librarian 
who had deployed NS Naloxone to multiple individuals on numerous occasions in the 
wake of an overdose, in a public library. I remember thinking, ‘that was certainly not 
what she signed up for’. Yet, she continues to carry and deploy Naloxone when the 
situation arises. I’m sure this woman did not expect this to be a function of her job as a 
librarian; nevertheless, she recognized a way to help and in turn she is saving the lives of 
parents, siblings, friends, etc. I reached a similar realization through the interview 
process. 
About half way through the third interview, I realized this isn’t about Naloxone, 
this is about law enforcement and their willingness to serve and protect, emphasis on 
protect, the public and each other. I had the opportunity to speak with six remarkable 
individuals, from different walks of life, who all made it astoundingly clear that they 
would carry Naloxone by choice, because when they put on their uniform they have a 
duty to protect. Today, protecting the public includes carrying Naloxone; tomorrow, 
protecting the public may require something completely different, either way, law 
enforcement will adjust, put their personal beliefs aside, and serve.  
Conclusion 
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First and foremost, I was extremely fortunate to have the opportunity to interview 
six law enforcement professionals, who truly embody what it means to be a police 
officer. I highly recommend sitting down with an officer to discuss a prevalent topic, as 
they were all filled with insight and experiences, far beyond my expectations. In today’s 
day and age, law enforcement officers, as a whole, are underappreciated and highly 
criticized, the conversations I had only solidified my deep appreciation and respect for 
the men and women in blue.  
Secondly, when I first started my doctoral program in 2015, I had a naive notion 
that by the time I completed this study, the opioid epidemic would be winding down, 
better addressed, and eventually over shadowed. Unfortunately, as I delved deeper in the 
available literature, books, interviews, documentaries, etc., I feared this would not be the 
case. The opioid epidemic has not only remained pertinent, but has continued to catch 
fire, evolving far beyond my initial expectations.  
Currently, I cannot turn on the TV, the radio, open a newspaper, peruse a 
bookstore, etc., without seeing some indication of the opioid epidemic. There are 
commercials for ‘over the counter Naloxone’, there are solicitors who call my phone with 
treatment options, book shelves are filled with first hand accounts of recovering addicts, 
and yet hundreds of individuals perish each week at the hand of an overdose. This 
epidemic does not discriminate, individuals from all walks of life have and will continue 
to be affected. Please take the time to educate yourself on the dangers of addiction and 
offer a hand to a friend in need. Together, we can ignite change and tackle this epidemic.  
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NOVA  
College of Arts, Humanities, and Social Sciences 
Appendix A: Informed Consent Form 
 
 
General Informed Consent Form 
NSU Consent to be in a Research Study Entitled 
A Multiple Case-Study Approach to Examine Police Officers Perceptions on 
Narcan Polices 
 
Who is doing this research study? 
 
College: Nova Southeastern University, College of Arts, Humanities, and Social 
Sciences   
 
Principal Investigator: Casey Gnann, (B.A., M.S.) 
 
Faculty Advisor/Dissertation Chair: Dr. Tina Jaeckle (B.S., MSW, M.S., Ph.D.)  
 
Funding: Unfunded 
 
What is this study about? 
 
This is a research study, designed to test and create new ideas that other people 
can use. The purpose of this research study is to develop a better understanding 
of law enforcements perceptions on the use of narcan in the field. Preliminary 
statistics for 2017, indicate opioid overdoses have continued to rise in the United 
States. As overdoses continue to rise, policy makers have continued to undergo 
fire for their failure to ignite change. Additionally, more and more police and 
Sheriffs departments have either enacted policy to equip officers with narcan, or 
have received backlash for their failure to do so. It does not appear that the 
opioid epidemic will slow down anytime soon; therefore, it is more necessary 
than ever to determine how such policies may affect those involved. 
 
Why are you asking me to be in this research study? 
 
You are being asked to be in this research study because you are an individual 
who has worked in law enforcement during the height of the opioid epidemic. 
This study aims to explore an issue related to the opioid epidemic, from the view 
of law enforcement.  
 
This study will include five people. 
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What will I be doing if I agree to be in this research study? 
 
While you are taking part in this research study, you will participate in one, in 
person, one-on-one interview, with me. The duration of the interview will range 
from 1-2 hours.  
 
Research Study Procedures - as a participant, this is what you will be doing:  
• Participating in one, one-on-one interview with me. This interview will 
range in duration from 1-2 hours.  
• Participants are required to be employed by Saint Johns County 
Sheriffs Office, and must have experience carrying narcan 
(administration is not required) 
 
Are there possible risks and discomforts to me?  
 
This research study involves minimal risk to you. To the best of our knowledge, 
the things you will be doing have no more risk of harm than you would have in 
everyday life.  
 
 
What happens if I do not want to be in this research study?  
 
You have the right to leave this research study at any time, or not be in it. If you 
do decide to leave or you decide not to be in the study anymore, you will not get 
any penalty or lose any services you have a right to get. If you choose to stop 
being in the study, any information collected about you before the date you leave 
the study will be kept in the research records for 36 months from the end of the 
study but you may request that it not be used.  
 
What if there is new information learned during the study that may affect 
my decision to remain in the study? 
 
If significant new information relating to the study becomes available, which may 
relate to whether you want to remain in this study, this information will be given to 
you by the investigators. You may be asked to sign a new Informed Consent 
Form, if the information is given to you after you have joined the study. 
 
Are there any benefits for taking part in this research study?  
 
There are no direct benefits from being in this research study. We hope the 
information learned from this study will provide readers a better understanding of 
the role of law enforcement officers in the opioid epidemic.   
 
Will I be paid or be given compensation for being in the study?  
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You will be reimbursed for any expenses you may incur by participating in this 
study. You will be reimbursed for gas expenses using the government rate of 
54.5 cents per mile. Participants will be asked at the start of the interview to 
inform the interviewer the amount of miles travelled to the interview. This amount 
will be doubled to account for the expenses of the return commute. If the 
participant incurs any parking fees, he/she will provide the interviewer with the 
price of the fee and the interviewer will write a check to reimburse the participant.  
 
You will also receive a $50 visa gift card; the gift card will be given at the start of 
the interview. If at any time the participant chooses to terminate the interview, 
he/she will not be expected to return the gift card.  
 
 
Will it cost me anything? 
 
There are no costs to you for being in this research study. 
 
Ask the researchers if you have any questions about what it will cost you to take 
part in this research study (for example bills, fees, or other costs related to the 
research). 
 
How will you keep my information private? 
 
Information we learn about you in this research study will be handled in a 
confidential manner, within the limits of the law and will be limited to people who 
have a need to review this information. In order to ensure the confidentiality of 
the participants, the researcher will not include personal identifying information. 
The researcher will store any documents, forms, or collected PII information in a 
safe location, which only the researcher has access. Any additional 
confidentiality concerns held by the participant will be discussed and handled 
accordingly. This data will be available to the researcher, the Institutional Review 
Board and other representatives of this institution, and any regulatory and 
granting agencies (if applicable). If we publish the results of the study in a 
scientific journal or book, we will not identify you. All confidential data will be kept 
securely in a locked filing cabinet in my home. All data will be kept for 36 months 
from the end of the study and destroyed after that time by shredding.   
 
Will there be any Audio or Video Recording? 
This research study involves audio recording. The researcher will be transcribing 
the interview recording following the interview. The researcher will transcribe the 
interview in her home, using headphones. This recording will be available to the 
researcher, the Institutional Review Board and other representatives of this 
institution. The recording will be kept, stored, and destroyed as stated in the 
section above. Because what is in the recording could be used to find out that it 
is you, it is not possible to be sure that the recording will always be kept 
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confidential. The researcher will try to keep anyone not working on the research 
from listening to or viewing the recording.  
 
Whom can I contact if I have questions, concerns, comments, or 
complaints? 
 
If you have questions now, feel free to ask me.  If you have more questions about 
the research, your research rights, or have a research-related injury, please 
contact: 
 
Primary contact: 
Casey Gnann (B.A., M.A.) can be reached at 561-302-9388. 
 
Research Participants Rights 
For questions/concerns regarding your research rights, please contact: 
 
Institutional Review Board 
Nova Southeastern University 
(954) 262-5369 / Toll Free: 1-866-499-0790 
IRB@nova.edu 
 
 
You may also visit the NSU IRB website at www.nova.edu/irb/information-for-
research-participants for further information regarding your rights as a research 
participant. 
 
 
All space below was intentionally left blank. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
  
 
 
 
136 
 
 
 
 
 
 
Research Consent & Authorization Signature Section  
 
Voluntary Participation - You are not required to participate in this study.  In the 
event you do participate, you may leave this research study at any time.  If you 
leave this research study before it is completed, there will be no penalty to you, 
and you will not lose any benefits to which you are entitled. 
 
If you agree to participate in this research study, sign this section.  You will be 
given a signed copy of this form to keep.  You do not waive any of your legal 
rights by signing this form.   
 
SIGN THIS FORM ONLY IF THE STATEMENTS LISTED BELOW ARE TRUE: 
• You have read the above information. 
• Your questions have been answered to your satisfaction 
 
 
 
 
Adult Signature Section 
I have voluntarily decided to take part in this research study. 
 
 
 
 
Printed Name of Participant 
 
 
 
 
 Signature of Participant 
 
 
  Date 
Printed Name of Person 
Obtaining Consent and 
Authorization 
 Signature of Person Obtaining Consent 
& Authorization 
  Date 
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Appendix B: Screening Questions 
 
1. Are you currently a law enforcement officer employed by the Florida Sheriffs 
Office? 
 
2. Are you required to carry narcan in the field? 
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Appendix C: Interview Framework Questions 
 
1. What is your name? 
2. What is your age? 
3. How long have you been in law enforcement? 
4. How long have you worked for the specific department? 
5. Can you please describe your thoughts on the policy which requires you to carry 
and administer narcan in the field? 
6. Can you please describe your thoughts on the utilization of harm reduction tactics 
in law enforcement elements? 
7. Have you been in a situation in which you administered narcan? 
8. Have you been in a situation in which you wish you had narcan available to 
administer?  
9. Do you have any reservations about using narcan in the field? 
10. Do you believe administering narcan is a medical procedure? 
11. Have you ever felt in danger when administering narcan? 
12. Do you feel law enforcement officers are well equipped to administer narcan in a 
situation in which paramedics are not present? 
13. Does carrying and administering narcan prevent you from focusing on other 
duties? 
14. Does carrying narcan affect your day to day interactions/responsibilities? 
15. Do you fear public backlash (given the current climate) if something were to go 
wrong in the use of narcan? 
